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 Introduction: Acute exercise, consisting of 1 to 3 bouts of 60 to 100 minutes, is 
capable of preconditioning the myocardium against ischemia-reperfusion (I/R) injury. 
We previously reported that elevated heat shock protein 70 (HSP70) is not required for 
this cardioprotective effect. The agent or agents that trigger and mediate this 
preconditioning effect are still not understood, but may involve the production of 
reactive oxygen species (ROS) during exercise as a trigger, and the production of nitric 
oxide (NO) by nitric oxide synthase (NOS) during I/R or uncoupling of mitochondrial 
respiration as mediators. The purpose of the present studies was to determine the role of 
these potential triggers and mediators in acute exercise-induced (AEI) cardioprotection. 
Methods: Rats were randomly assigned to seven treatment groups: sedentary (SED); 
 
vii
two days of treadmill exercise at 20 m/min, 6-degree grade, for 60 minutes (RUN); 
sedentary and injected with 100 mg/kg N-(2-Mercaptopropionyl)glycine (MPG, a 
potent ROS scavenger) (SED/MPG); exercise and injected with MPG (RUN/MPG); 
sedentary then perfused with 100 µM Lω-Nitro-L-arginine methyl ester hydrochloride 
(L-NAME, a competitive inhibitor of NOS) (SED/L-N); exercise then perfused with L-
NAME (RUN/L-N); exercise in a 4°C environment (to prevent HSP70 increase) then 
perfused with L-NAME (CRUN/L-N). Twenty-four hours following the second 
exercise bout, or MPG injection, isolated-perfused working hearts were subjected to 
22.5 minutes of global ischemia followed by 30 minutes of normoxic reperfusion. 
Portions of left ventricle were analyzed for several putative mediators of exercise-
induced cardioprotection including: HSP70, inducible (iNOS) or endothelial (eNOS) 
NOS, manganese superoxide dismutase (MnSOD), and catalase. Results: All exercise 
groups displayed improved recovery of cardiac function vs. sedentary groups, which 
was not inhibited by MPG injection or L-NAME perfusion. Also, all exercise groups 
had improved efficiency post-ischemia, suggesting that uncoupling does not mediate 
AEI cardioprotection. The only increases in protein expression were: HSP70 in RUN, 
RUN/MPG, and RUN/L-N; eNOS in CRUN/L-N; and catalase in SED/MPG and 
RUN/MPG. Conclusions: AEI cardioprotection appears to not be triggered by ROS 
production, is mediated by changes independent of eNOS or catalase expression and 
uncoupling, and can occur in the absence of increases in HSP70, MnSOD, and iNOS. 
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 Several researchers have reported that chronic exercise training can improve the 
ability of the heart to recover pump function following a period of ischemia (25, 26, 28, 
42, 61, 72, 81, 95, 103, 128, 152). It is now known that only a few bouts of exercise 
(acute exercise) are required to receive the cardioprotective benefits previously only 
attributed to chronic training programs (43, 49, 58, 65, 93, 98, 124, 145, 158, 172, 173). 
However, the mechanisms that provide this protection are not fully understood. In 1995, 
Locke et al. (98) suggested that the cardioprotection provided by three days of exercise 
was due to an exercise-induced increase in the myocardial concentration of heat shock 
protein 70 (HSP70), because it positively correlated with increased functional tolerance 
to ischemia-reperfusion (I/R) in a Langendorff heart perfusion model. To determine 
whether increased HSP70 is required for acute exercise-induced cardioprotection, we 
designed an experiment to prevent a rise in the concentration of HSP70 by exercising 
animals in the cold (158). Not only did we find improved cardioprotection against I/R 
injury 24 hours after exercise in the cold, we also found that enhanced protection was 
present after only a single bout of exercise. Our finding that elevated HSP70 is not 
required for the cardioprotection induced by acute exercise was subsequently confirmed 
by Hamilton et al. (58) and Lennon et al. (93). While these studies were able to 
dissociate HSP70 from acute exercise-induced cardioprotection, the mechanisms 
responsible for the protection were not addressed and are still not well understood. 
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A subsequent study carried out in our lab (157) provided some insight into other 
possible mechanisms underlying exercise-induced cardioprotection. Reactive oxygen 
species (ROS) are produced in the myocardium during exercise and I/R, and have been 
widely implicated in the damage associated with I/R injury (30, 167). Cardiac 
dysfunction due to ROS can be modeled by exposing an isolated-perfused heart to pro-
oxidants such as hydrogen peroxide (H2O2) (143). We found that chronic exercise did 
not protect cardiac pump function in response to H2O2 exposure; however, the release of 
the cytosolic enzyme lactate dehydrogenase (LDH), an indicator of sarcolemma 
damage, was attenuated by exercise training. One of the most interesting, and relevant, 
findings of this study was that exercise enhanced the coronary flow (CF) response to 
H2O2, which was potentially due to an increase in nitric oxide synthase (NOS) 
following exercise training. When we paired this finding with our previous observation 
that CF was significantly elevated following I/R in the group that exercised in the cold 
(158), we made the following speculation: the mechanism by which acute exercise 
provides cardioprotection, independent of HSP70, could be related to a ROS-induced 
increase in CF through the action of nitric oxide (NO) produced by an increased 
concentration of NOS in the myocardium. 
 The observation, of a positive relationship between CF and increased 
cardioprotection marked the beginning of our investigation into the triggers (signal/s 
that cause adaptations within the myocardium) and the mediators (agent/s responsible 
for providing the direct protection) of cardioprotection. As previously mentioned, the 
production of NO during reperfusion may have a cardioprotective effect, which has 
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been characterized by numerous investigators (17); however, other changes in the 
myocardium may occur as a result of exercise that allow for redundant mechanisms of 
protection. ROS production during I/R appears to be a major contributing factor to 
myocardial damage and dysfunction and some investigators believe that suppression of 
the I/R-induced production of ROS could prevent the damage associated with I/R 
injury. One method proposed to attenuate the rise in ROS during I/R is an uncoupling of 
mitochondrial respiration (16, 132, 159). Additionally, increases in various anti-
oxidants could also serve the same purpose of decreasing the concentration of ROS in 
the myocardium. Antioxidant enzymes have been observed to increase (43, 173) or not 
increase (98) with acute exercise, but do not appear to be involved with chronic exercise 
induced cardioprotection (61). Attenuating the rise in ROS during I/R would appear to 
have protective effects for the myocardium; however, their presence during exercise 
may be required to trigger cardioprotective changes (2, 77, 82, 156, 160, 179, 180). 
Similarly, the production of NO during exercise may be an essential trigger for related 
cardioprotective changes (1, 4). 
 The purpose of this study is to elucidate the mechanisms by which 2 days x 60 
minutes of exercise triggers cardioprotective adaptations and to determine which 
agent(s) are responsible for mediating the cardioprotective response. Through the 
execution of the experiments outlined herein, an attempt will be made to answer four 
primary questions pertaining to the triggering and mediation of cardioprotection by 
acute exercise. First, is there a difference in cardiac efficiency (oxygen utilization 
relative to external work being performed) following acute exercise and if so, are any 
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differences due to increases in uncoupling protein 2 (UCP2)? Second, does an acute 
exercise-induced increase in ROS trigger the cardioprotective response? Third, does an 
acute exercise-induced increase in NO trigger the cardioprotective response? Finally, 
does NOS mediate exercise-induced cardioprotection against I/R injury and will 
inhibition of NO production during perfusion block cardioprotective changes? Through 
the information gained during the investigation of these objectives, a better 
understanding of acute exercise-induced cardioprotection will be gained, which will aid 




 Because cardiovascular disease is prevalent in America, actions must be taken in 
order to prevent deaths and to improve one’s chances of surviving a heart attack. Many 
different approaches, including exercise, have been investigated in the process of 
addressing this problem. Until recently, the common belief was that in order to receive 
cardioprotective benefits, exercise must occur on a regular basis. This dosage of 
exercise is well above what many Americans regularly perform. Previous work has 
demonstrated that a single bout of exercise is capable of inducing protective changes in 
the myocardium against I/R injury, similar in magnitude to those found after months of 
regular exercise. A number of upstream cell-signaling events, including activation of 
protein kinase C epsilon (PKCε), appear to be essential for the development of 
cardioprotection; however, the specific signals that trigger this activation and the 
downstream agents that mediate cardioprotection are not fully understood. The findings 
of this study will help elucidate the link between acute exercise and the specific 
mechanisms that trigger and mediate the cardioprotective response to acute exercise. 
These findings will further our understanding of normal cardioprotective responses, so 
that future cardioprotective interventions and therapies may be developed. 
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Review of Related Literature 
 Background. It is well-documented that physical activity lowers the risk of 
cardiovascular disease and reduces deaths resulting from heart attacks (35, 91, 116); 
however, the mechanism(s) underlying the observed protection were not, and are still 
not, fully understood. One of the earliest studies to directly address the question of 
whether or not exercise induced changes in the heart muscle itself was carried out by 
Bowles et al. (25) who found that 11 weeks of treadmill exercise provided protection 
against I/R injury in an isolated-perfused rat heart. A common cause of damage to the 
myocardium in humans is ischemic injury due to temporary (total or partial) blockage 
of the coronary vasculature (122). The isolated-perfused heart model (diagrammed in 
Figure 1) is unique in that it allows for direct measurement of cardiac function, 
independent of any nervous, hormonal, or hemodynamic influences (119). The findings 
of Bowles et al. represented a huge leap in the understanding of exercise-induced 
modification of cardiovascular health, but the study provided little insight into the 
mechanisms of protection or the time course for the achievement of a cardioprotective 
effect. The American Heart Association now categorizes lack of physical activity as a 
risk factor for cardiovascular disease, which is the leading cause of death in the United 
States. Recent studies have demonstrated that as few as one day of exercise can provide 
a cardioprotective effect similar to that observed following several weeks of exercise. 
Exploration of the acute exercise-induced cardioprotection phenomenon will aid in the 
development of reasonably implemented exercise programs, and as the physiological 
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mechanisms responsible for protecting the myocardium are better understood, 
additional cardioprotective interventions may be developed. 
 Ischemia and Preconditioning. Cardiac dysfunction due to I/R injury is normally 
grouped into two distinct types of injury, myocardial stunning and the more severe and 
irreversible myocardial infarction caused by necrosis and/or apoptosis (21). The exact 
mechanism(s) by which myocardial stunning causes dysfunction is not known, but it 
has been proposed that increased ROS production, calcium overload, or a combination 
thereof may be responsible. The amount of cardiac function that is recovered following 
I/R will depend upon the degree of damage, which is directly related to the duration of 
ischemia. Although stunning is not as severe as necrosis of myocardial tissue, if the 
heart is not able to recover from a period of myocardial stunning, the duration of the 
ischemic insult will increase thereby further increasing myocardial damage. Therefore, 
protection against the specific phenomenon of myocardial stunning is a valid clinical 
objective. 
Preconditioning is a phenomenon by which a stress applied to a tissue or organ 
initiates a change or changes, leading to protection against subsequent exposures to 
similar or different types of stress (18). Methods currently known to precondition the 
myocardium include: exercise (25, 98, 158), ischemic preconditioning (117), heat stress 
(39, 69), oxidative stress (57, 138), stretch (123), and certain pharmacological 
interventions (165). Although a majority of the research into the preconditioning 
phenomenon has been carried out using cell cultures and laboratory animals, there is 
significant clinical evidence, in humans, for a cardioprotective effect of a 
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preconditioning stimulus (15, 104, 108). The time frame over which preconditioning 
occurs can be divided into two distinct periods, the early phase and late phase, with 
each protecting by very different mechanisms. Early phase protection develops within 
minutes following a preconditioning stimulus, may last as long as 2 to 3 hours, and is 
primarily mediated through the post-translational modification of existing proteins. Late 
phase protection is mediated through de novo synthesis of protective proteins, develops 
within 12 to 48 hours, and may last as long as 9 days following a preconditioning 
stimulus. Some of these putative protective proteins synthesized include HSP70 and 
manganese superoxide dismutase (MnSOD). Another distinct difference between the 
two phases of protection is that late phase preconditioning can protect against both 
infarction and stunning, but early phase preconditioning only appears to protect solely 
against infarction (18). When considered together, all of the various aspects of 
myocardial damage and the numerous methods known to protect the myocardium 
constitute numerous potential investigative targets. Therefore, the current investigation 
is limited to the examination of only a limited number of the specific aspects of these 
phenomena including the late phase preconditioning of the myocardium against 
ischemia-induced myocardial stunning by acute exercise. 
Acute Exercise. In 1995 a group of investigators found that exposure to a single, 
15 minute, sub-lethal heat-stress or to as few as 3 days (but not a single day) of 
treadmill exercise could precondition against I/R injury in a Langendorff-perfused heart 
(98). Additionally, they found that improved post-ischemic recovery of mechanical 
function resulting from exercise or passive heat-stress was significantly correlated with 
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an increase in heat shock protein 70 (HSP70). This was an important finding, as no 
previous reports had demonstrated such a strong effect of only an acute exposure to 
exercise, but it was not clear if the observations of the investigators would be found 
when myocardial function was evaluated in the more sensitive and physiologically 
relevant isolated working heart. Subsequently, we performed a series of experiments to 
determine whether or not one or three days of exercise could provide similar protection 
in the isolated working heart (158), which led to some interesting findings. First, the 
findings of Locke et al. (98) were confirmed in the working heart model, as 3 days of 
treadmill exercise protected against I/R injury in the isolated working heart. Second, it 
was determined that one day of exercise could provide a similar degree of protection, 
which may have been due to the increased sensitivity of the working heart model, or to 
a slightly longer running time (60 vs. 100 minutes). Third, a similar degree of protection 
was provided when rats were run for one day in a cold (8°C) environmental chamber, 
thereby preventing a rise in core temperature (~41°C) and increase in HSP70 that 
normally accompanies treadmill exercise in a 20°C environment. Therefore, an increase 
in HSP70 expression was not required for improved cardioprotection. Finally, we 
observed that the coronary flow (CF) during reperfusion was elevated in the cold 
exercisers compared to all other groups. A potential explanation for this observation is 
that cold running resulted in increased production of myocardial NO, a potent 
vasodilator and possible mediator of protection against I/R injury (17). The agent or 
agents responsible for providing the protection in the preceding experiment and the 
signals that initiated the development of the cardioprotective phenotype are not 
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completely understood. The remaining sections of this review will explore the current 
knowledge of cardioprotection and I/R injury, and discuss a series of proteins and 
pathways that may be involved in exercise-induced cardioprotection. 
Oxidative Stress. The flow of electrons through the electron transport chain is a 
necessary step in the aerobic production of ATP in mitochondria; however, a 
consequence of this process can be production of ROS including superoxide (·O2-), 
hydrogen peroxide (H2O2), and the hydroxyl radical (·OH) (Figure 2). Peroxynitrite 
(ONOO-), a reactive nitrogen species, is also produced during this process (Figure 2). 
One-electron reduction of O2 appears to be the primary source of ROS in the cell; 
however, there is considerable debate as to where specifically in the electron transport 
chain the suspect electrons originate (Complex I, Complex II, or ubiquinone), and to the 
conditions under which they can be produced (state 3 vs. state 4) (see (161) and (92) for 
review). Additionally, it has been proposed that ROS production could originate from 
other sources in the rat myocardium including NADPH oxidase (169) and xanthine 
oxidase (31, 135), but the production of ROS from xanthine oxidase may be a rat 
model-specific phenomenon (31) as the enzyme does not appear to be present in rabbit 
(50) or human (51) hearts. 
Experimental data from studies of intact tissues support the production of ROS 
during exercise (10, 121, 137) and I/R (9, 53); therefore, understanding the mechanisms 
capable of decreasing the damage due to ROS during I/R will be essential when 
describing the cardioprotective phenotype. It is important to note that the ROS produced 
during exercise may (96) or may not (10, 121, 137) damage the myocardium; however, 
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they may play an important role in the development of cardioprotection, which will be 
discussed below. Additionally, total abrogation of the production of ROS may not be an 
acceptable solution to preventing I/R injury as a limited presence during reperfusion 
may actually enhance recovery (82) and production during exercise may trigger a 
preconditioning response (36). Two strategies proposed for reducing the damage caused 
by ROS during I/R include: 1) reducing the amount of ROS produced or 2) increasing 
the amount of radical scavengers (including: superoxide dismutase (SOD), catalase 
(CAT), and glutathione peroxidase (GPX)) available to dispose of ROS (Figure 2). 
Mitochondrial Uncoupling. Electrons escaping from the electron transport chain 
have been implicated in the production of ROS resulting in oxidative/reductive stress. 
Studies performed on isolated mitochondria suggest that during state 4 respiration (No 
ADP, highly reduced electron carriers) ROS production is high while during state 3 
respiration (ADP present, high rate of electron flux) ROS production is dramatically 
reduced (63). The addition of ADP allows for high rates of ATP production, and during 
this process the proton gradient across the inner mitochondrial membrane is partially 
dispersed. This physiological dispersion of the proton gradient, and resulting oxidation 
of the components of the electron transport chain, can also be accomplished through the 
addition of pharmacological uncouplers of mitochondrial respiration such as 
dinitrophenol (DNP). Cardiac efficiency is the measure of the amount of cardiac work 
(COxSP) divided by the amount of oxygen that the heart is consuming at any given 
time. If the assumption is made that the efficiency of force production from the 
hydrolysis of ATP is not affected during perfusion and that the amount of work that the 
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heart is performing does not change, any increases in the amount of oxygen being 
consumed would be due to a decreased efficiency of energy production. In fact, a small 
dose of DNP has been shown to decrease the production of ROS (16) and to protect 
against I/R injury in isolated-perfused hearts (111). It is also important to note that DNP 
decreases cardiac efficiency, before and after I/R in isolated-perfused hearts (16), which 
one would expect to observe with an uncoupling agent. 
Uncoupling proteins. There is evidence for a physiological method of 
mitochondrial uncoupling in the myocardium through the action of a protein known as 
uncoupling protein 2 (UCP2) (22). Although an entire family of uncoupling proteins 
exists, UCP2 is the predominant isoform expressed in the heart (22). Furthermore, 
transfection of either UCP1 (14) or UCP2 (159) into cardiomyocytes resulted in 
protection against hypoxia and ROS induced damage. To date, no studies have 
evaluated the effects of acute exercise on UCP2 expression; however, one study found 
that chronic exercise decreases myocardial UCP2 mRNA expression (23). It would 
appear to be counterintuitive to investigate a protein which seems to be down-regulated 
with exercise, but the responses of the myocardium to chronic vs. acute exercise may 
differ substantially, and mRNA levels at a single time point may not accurately reflect 
protein expression (46, 114). It should also be noted that exposure to a cold 
environment increases UCP2 mRNA in the hearts of rats (24), which at first glance 
would appear to complicate the interpretation of any results from animals exercising in 
a cold environment. However, we have previously determined that increased heat 
production from running is sufficient to prevent hypothermia. The temperature of the 
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animals while running is an important variable in acute exercise-induced 
cardioprotection and will be discussed in following sections. 
Antioxidants. Antioxidant enzymes are an essential part of the physiological 
defense mechanism (Figure 2) and over-expression of many of the predominant 
antioxidants, including: MnSOD (34), CuZnSOD (33), CAT (94), and GPX (140), has 
been demonstrated to protect the myocardium. However, regulation of their expression 
in response to a preconditioning stimulus is the subject of much debate. Although 
antioxidants clearly have protective effects and are constitutively expressed, their 
contribution to exercise-induced cardioprotection is questionable and they do not appear 
to mediate the late-phase protection provided by ischemic preconditioning (155). A 
study from our laboratory indicates that myocardial antioxidant enzymes are not 
elevated after adapting to a chronic exercise program and that exercise-induced 
protection against I/R injury associated with chronic exercise is not dependent upon an 
up-regulation of the expression of the predominant antioxidant enzymes (61). However, 
there is some evidence that antioxidant enzymes may be increased during the early 
phase of adaptation to a chronic exercise stress. For example, Somani et al. (144) 
reported increases in MnSOD, CAT, and GPX activity following a single exhaustive 
bout of exercise by previously sedentary rats. The findings of these authors are 
somewhat suspect, since the animals were sacrificed immediately following the 
exhaustive exercise bout at an intensity representing approximately 100% of VO2max. 
If increases in enzyme activity represent an increase in protein content, this would 
require that all increases in protein expression occur in a time frame less than 100 
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minutes, which may not be possible due to the temporal constraints of transcription and 
translation. A potential explanation for the unusual findings of the authors can be found 
in a study by Yamashita et al. (173), who report that MnSOD specific activity is 
increased 30 minutes following a single bout of exercise, but that the concentration of 
the protein does not increase until 48 hours following cessation of exercise. 
Additional studies from different groups of investigators further complicate our 
understanding of the effect of acute exercise-induced cardioprotection. Three separate 
studies from the same laboratory found that acute exercise may increase MnSOD and 
HSP70 only (43, 58), or alternatively, only CAT and HSP70 but not CuZnSOD or 
MnSOD (93). The increase in HSP70 and/or MnSOD are in agreement with other acute 
exercise studies (65, 98, 173), but increases in CAT with acute exercise have not been 
reported in other studies (98). Overall, a consensus has yet to be reached among 
investigators regarding the expression of MnSOD and CAT after exercise. This may be 
due to the method by which the enzymes are measured (activity vs. protein content 
(173)), the strain of the animal (Sprague Dawley (43, 58, 93, 98) vs. Wistar (173) vs. 
Fisher 344 (144)), gender of the animal (male (93, 98, 144, 173) vs. female (43, 58)), 
the number of days considered to be acute exercise (1 (144, 173), 2 (65), 3 (98), 8 (93), 
9 (58), or 10 (43)), or age (145). To our knowledge, no studies have found CuZnSOD to 
be elevated after acute exercise and the only study to report an increase in GPX is the 
study by Somani et al. discussed above as having some experimental design problems 
(144). Therefore, due to the fact that CuZnSOD and GPX do not appear to change in 
response to acute exercise at any age (145) they are not evaluated in the present study. 
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The current study will attempt to clarify the myocardial response to acute exercise, but 
more importantly, any differential patterns of expression in response to the various 
experimental conditions may explain some of the differences reported in the literature. 
Reactive Oxygen Species as a Trigger of Cardioprotection. ROS appear to play 
a role in the damage and dysfunction due to I/R, but their production during exercise 
may play an essential role in signaling the preconditioning of the myocardium (77, 173, 
179). Initially, two groups of investigators found that the administration of a 
combination of antioxidants; including SOD, CAT, dimethylthiourea (DMTU), and N-
(2-mercaptopropionyl)glycine (MPG), could block the late-phase preconditioning effect 
of ischemic preconditioning (149, 154). However, subsequent studies have reported that 
administration of MPG alone shortly before a preconditioning stimulus is sufficient to 
block the preconditioning effects of ischemic (156, 160), heat stress (2, 175), or ROS-
donor exposure (153, 179) preconditioning. 
Whether antioxidant administration prior to exercise will block exercise-induced 
cardioprotection is unclear, as the only two studies to evaluate this phenomenon 
reported conflicting results (59, 173). Hamilton et al. (59) reported that a diet high in 
antioxidants will improve protection against stunning in response to short I/R and that 
antioxidant diet plus acute exercise will further enhance recovery of mechanical 
function. In response to long I/R (potential myocardial necrosis/apoptosis), antioxidant 
diet plus exercise, antioxidant diet alone, and exercise alone, all resulted in similar 
infarcts compared to sedentary animals on a control diet; however, the combination of 
antioxidant diet and exercise did not produce better results than either individually. 
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Hamilton et al. also found that MnSOD was increased by exercise regardless of diet. 
These are the opposite of those reported by Yamashita et al. (173) who found that MPG 
administration plus exercise abrogated the increases in MnSOD and I/R tolerance 
(infarct size) that occur 48 hours after a single exercise bout without MPG. 
There are a number of issues to be addressed in the study by Hamilton et al. that 
may be contributing to the differences reported. First, the lack of an abrogating effect, 
with respect to functional differences between the exercised vs. exercised with 
antioxidants, may be due to the low sensitivity and decreased control of experimental 
conditions in the in-vivo heart perfusion. This is apparent in that sedentary animals 
decreased function approximately 30% and exercised animals recovered greater than 
100% following ischemia. The magnitude of the difference between the two exercising 
groups is very small, and any protective effects could be due solely to the antioxidant 
exposure. It is interesting to note that the expression of HSP70 in response to the 
exercise was blocked by the antioxidant diet in a manner similar to that observed when 
heat-stress preconditioning is blocked by MPG (175), and there is significant evidence 
for ROS-mediated mechanism of HSP70 expression(86, 120, 153). Second, prior to 
performing exercise the animals were fed the antioxidant diet for 6 weeks resulting in a 
chronic increase in the total antioxidant capacity of the heart, as opposed to being given 
a single dose of MPG, which is short acting and provides antioxidant protection during 
the exercise sessions only. Third, the animals were exercised for a total of 10 days, 
including the habituation period, which may indicate a pattern of chronic exercise 
adaptation rather than an acute adaptation, protecting via alternate mechanisms. Due to 
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the fact that Yamashita et al. (173) only evaluated 20 minutes of exercise-induced 
protection against long I/R injury and that the experimental design of the study by 
Hamilton et al. leaves some uncertainty, the adaptive response of the myocardium to 
acute exercise is still not apparent. Clearly, additional work will be required in order to 
determine the role of ROS in acute exercise-induced cardioprotection and how the 
various protective responses are triggered. 
HSP70 expression and regulation. The increased synthesis of HSP70 in 
response to heat-stress, first observed in 1962 (130), has a widely recognized role in 
cellular protection (80), and has emerged as a primary mediator of cardioprotection due 
to preconditioning (80, 85, 89). The first study to demonstrate heat stress-induced 
protection from ischemia-induced damage, mediated by HSP70, was carried out by 
Currie et al. in 1988 (39). Subsequently, adenovirus transfection studies designed to 
over-express HSP70 in rat hearts indicated a direct role of the protein in protection 
against dysfunction and necrosis after an ischemic insult (150, 151). Studies from our 
laboratory suggest that increased body temperature is the primary signal for increased 
synthesis of HSP70 following either acute (158) or chronic (61) exercise. However, the 
minimal myocardial temperature required for signaling an increased HSP70 production 
is unclear as no studies to date have reported a direct measurement of myocardial 
temperature during exercise, most likely due to the invasive procedures involved with 
such a measurement. Rectal temperature is commonly used as an indicator of core 
temperature (29, 43, 54, 58, 61, 110, 134, 142, 158) and should provide a relatively 
accurate representation of the core temperature of the animal during exercise. The 
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minimal rectal temperature required for increased synthesis of HSP70 in response to 
exercise has been reported to be 39.9°C (110), however, previous studies have reported 
that animals running at similar intensities have much higher (~44°C vs. ~40°C) rectal 
temperatures (29, 134). The general consensus in the literature is that there is an 
absence of heat stress-mediated effects in whole organisms below 39°C (109), and the 
animals to be exercised in this study should be either well above or well below this 
threshold as indicated in previous studies (158). 
In order to understand how acute exercise triggers cardioprotection, with or 
without HSP70, the regulation of HSP70 expression must be understood. Once the basic 
mechanisms controlling this process are understood, it will become clear that there is 
significant overlap and redundancy in the regulation of the entire cardioprotective 
response and that the regulation of cardioprotection is simply a balance between 
redundant mechanisms. The primary transcription factor responsible for controlling 
HSP70 is heat shock factor-1 (HSF1), and transcriptional control is regulated in part by 
PKCε (80, 89). PKCε is an important component of the cell-signaling mechanism of the 
myocardium (163) and is capable of phosphorylating a number of different proteins, 
including HSF1 (48, 107). The activation of HSF1 through phosphorylation facilitates 
the transcription of HSP70 in response to heat stress by promoting the trimerization 
HSF1, which can then bind to the heat shock element in the promoter region of the HSP 
gene to increase transcription (47). The activation of PKCε appears to be mediated by 
the production of both ROS and NO (5, 7, 171), and the over-expression of activated 
PKCε has a clear cardioprotective effect (6, 38). The information available regarding 
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acute exercise, which produces ROS and NO, suggests that a single bout of exercise 
activates PKCε and provides a cardioprotective effect (32, 172). Therefore any 
increases in HSP70 following acute exercise may be due to the trimerization of 
phosphorylated HSF1 and the cardioprotection provided by acute exercise in the cold 
could be mediated by the up-regulation of other cardioprotective targets also controlled 
by PKCε. As with many cellular regulation processes the expression of HSP70 can 
regulate its own expression through feedback inhibition of the activation of PKCε (48). 
Therefore, one would assume that if HSP70 expression is not increased in response to 
an acute stress (exercise), and that the heat-stimulated trimerization of HSF1 is the only 
absent stimuli, that other triggers of cardioprotection, including ROS and NO, could 
hyper-activate PKCε and increase other cardioprotective proteins, including NOS. 
Nitric Oxide as a Trigger of Cardioprotection. Nitric oxide is claimed to have a 
dual role of triggering and mediating cardioprotection (17). There is strong evidence for 
a triggering effect of NO from studies reporting that NO donors are capable of inducing 
a cardioprotective effect (8, 64, 102, 127, 153), and that inhibitors of NOS are capable 
of blocking preconditioning stimuli of pharmacological agents (12, 62), ischemia (131), 
or heat-stress (74). The physiological source of NO that triggers preconditioning 
appears to be eNOS as the non isoform specific inhibitor Lω-Nitro-L-arginine methyl 
ester hydrochloride (L-NAME) is capable of blocking a preconditioning response, 
whereas the iNOS-specific inhibitor aminoguanidine does not have the same abrogating 
effect (20). The preconditioning effect of NO may be mediated through PKCε, 
potentially requiring ROS for the formation of ONOO- as the stimulating agent (7, 153). 
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The expression of HSP70 may be linked to NO production as administration of 
exogenous NO donors can increase expression of HSP70 (101, 170) and inhibitors of 
NOS are capable of blocking heat stress-induced increases in HSP70 (78, 79, 100). 
Activation of PKCε may be required for the stimulation of increased HSP70 expression, 
but it may also regulate the transcriptional activity of iNOS (73). The preconditioning 
effects of pharmacological agents (181), ischemia (73, 166), and heat stress (1) all 
appear to trigger cardioprotection mediated by iNOS, and the cardioprotective effect 
can be blocked by either iNOS gene knockout (71) or NOS inhibitors (1, 27, 73). The 
only study to evaluate NOS expression following acute exercise reports that there is no 
increase in mRNA for any of the three isoforms (70), which does not resemble the 
pattern observed with heat-stress, pharmacological, or heat stress preconditioning, but 
could be due to the fact that the authors missed the window of expression by measuring 
mRNA immediately following exercise. 
Nitric Oxide as a Mediator of Cardioprotection. The preceding paragraph 
outlined the role of NO as a trigger of cardioprotection, but NO also plays a role in 
mediating protection against I/R injury. NO production is elevated in the ischemic and 
post-ischemic myocardium (90, 164), and the overwhelming majority of studies to 
evaluate this phenomenon report that it has a protective effect upon the myocardium 
(17). Exogenous NO administration during perfusion has a protective effect (11, 12, 66, 
75, 125), and the protective effects of pharmacological (12, 62), ischemic (20, 131), or 
heat-stress (1, 74) preconditioning can be blocked by NOS inhibitors. The precise 
mechanism by which NO protects is not known but possibilities include: inhibition of 
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calcium overload, activation of mitochondrial KATP channels, or antioxidant actions (see 
(17) for review). Recent evidence suggests that NO may exert protective effects through 
the activation of guanylate cyclase to produce cGMP (84). Only one study to date has 
examined the role of NOS in acute exercise-induced cardioprotection (4). The authors 
report that the iNOS-specific inhibitor aminoguanidine could block the protective 
effects of 21 minutes of treadmill exercise against 25 minutes of in-vivo coronary 
occlusion; however, the intensity of the exercise was very low, the duration of exercise 
was very short, and the measure of recovery used (% survival) was highly variable. 
Perfusion with aminoguanidine not only decreased survival in the exercised animals but 
also decreased the percent survivability to 0% for the sedentary animals. Therefore, it is 
not clear if aminoguanidine was blocking a protective effect or causing myocardial 
dysfunction independent of its inhibitory effects, and any increases in NOS could be 
due to the highly variable method of measuring NOS enzymatic activity rather than 
content. The results of the present study should help to clarify the role of NOS in acute 
exercise-induced cardioprotection. 
Justification for Experimental Parameters. During the course of the present 
study two non-physiological inhibitors are used to elucidate the triggers and mediators 
of acute exercise-induced preconditioning and the concentrations of inhibitors used are 
based upon the results of previous investigations. MPG is selected based upon its ability 
to scavenge •OH in vivo (19) and in vitro (148), and its ability to readily cross cell 
membranes (44). MPG is injected into animals at a concentration of 100 mg/kg prior to 
treadmill running, with the intention of blocking the triggering of preconditioning 
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provided by ROS, which is consistent with studies observing an abrogating effect of 
MPG upon either heat-stress (2, 174), ischemic (156, 160), or exercise (173) 
preconditioning. Following an IP injection of MPG, the concentration reaches a 
maximum concentration 15 minutes following injection, and will decrease to 50% by 
one hour (44), which allows for the concentration to remain at an appropriate level 
during the exercise bout to retain its scavenging capacity. 
NOS is inhibited through the administration of L-NAME both during exercise 
and during isolated perfusion. L-NAME was selected over other NOS inhibitors (129) 
based on the fact that it is a competitive inhibitor of all isoforms of NOS and that it has 
a well documented role in the inhibition of preconditioning stimuli (1, 3, 62, 68, 168). 
L-NAME is injected into animals at a concentration of 50 mg/kg, 15 minutes prior to 
initiation of the acute exercise bout, for determination of the role of NOS in the 
cardioprotective effect. This concentration blocks heat-stress induced preconditioning 
(3), while lower (68, 87) and higher (56, 97, 168, 176) concentrations successfully 
inhibit NOS in other exercise studies. For determination of the role of NO in mediating 
preconditioning, L-NAME is included in the perfusate at a concentration of 100 µM, 
which blocks the preconditioning effects of either pharmacological (12, 62), ischemic 
(131), or heat-stress preconditioning (74). It has been reported that 100 µM is the 
minimum concentration required for 100% inhibition of NOS (126), and further support 
for the use of 100 µM L-NAME is found in studies reporting that 100 µM L-NAME 
does not alter the response to I/R injury in the absence of a preconditioning effect (162), 
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and that extremely low concentrations (2 µM) may actually improve recovery from I/R 
injury (83). 
Although we have found previously that a single day of exercise is sufficient to 
provide a cardioprotective effect (145, 158), 2 days of exercise was selected for this 
study. This selection is based on the observations of some investigators that the 
protective effect of acute exercise peaks 48 hours after a single exercise bout or 
following other preconditioning stimuli (76, 173). Therefore, two bouts of exercise 
assure that all of the protective agents are in place. The rats are run for an hour at a 
speed of 20 m/min up a 6-degree grade, on both days, which represents approximately 
75% of their maximal aerobic capacity (VO2max) (25). 2 days of exercise will still allow 
evaluation of the acute exercise phenomenon; however, it will fall into a period of late-
phase recovery overlapping other various exercise interventions found in the literature. 
The series of experiments described herein attempt to address the question of what are 
the triggers and mediators of acute-exercise induced cardioprotection, as it has already 
been unequivocally established that acute exercise can precondition the myocardium 
against many different types of damage. 
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 Subject Description 
 The subjects in this experiment are Male Fischer 344 (F-344) rats obtained from 
the National Institute on Aging (NIA) and housed on the campus of The University of 
Texas at Austin. The rats were 4-6 months old and weighed between 300-350 g (Table 
1), and were divided into nine different treatment groups: sedentary (SED); two days of 
treadmill exercise at 20 m/min, 6-degree grade, for 60 minutes (RUN); sedentary / 
injected with 100 mg/kg MPG (a potent ROS scavenger) (SED/MPG); exercise / 
injected with MPG (RUN/MPG); sedentary / perfused with 100 µM L-NAME (a 
competitive inhibitor of NOS) (SED/L-N); exercise / perfused with L-NAME (RUN/L-
N); exercise in a 4°C environment (to prevent HSP70 increase) / perfused with L-
NAME (CRUN/L-N); sedentary / injected with 50 mg/kg L-NAME (SED/-NOS); 
exercise / injected with L-NAME (RUN/-NOS). 
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 Questions and Hypothesis 
 The purpose of the experiments outlined herein is to answer four primary 
questions. In answering these questions, observations of a number of expected changes 
in cardiac function and protein expression will be made, which are as follows: 
Question 1) Will 2 days of treadmill exercise in rats induce a cardioprotective effect 
mediated by an uncoupling of mitochondrial respiration? If so, the following 
changes may occur: 
1) A decrease in the cardiac efficiency (COxSP/O2 consumption), prior to 
and 30 minutes following ischemia in RUN vs. SED. 
2) An increase in the concentration of uncoupling protein 2 (UCP2) in the 
myocardium of RUN vs. SED. 
Question 2) Will the production of ROS in the myocardium during exercise trigger 
the cardioprotective effect of 2 days of treadmill exercise in rats? If so, the 
following changes may occur: 
1) Recovery of cardiac function (COxSP), 30 minutes following I/R will be 
greater in RUN vs. SED. This improvement in recovery will be blocked 
by the administration of MPG prior to exercise in RUN/MPG. 
2) The expression of various cardioprotective proteins will increase in RUN 
vs. SED including: HSP70, CAT, MnSOD, iNOS, nNOS, and eNOS. 
These increases in protein expression will be blocked by the 
administration of MPG prior to exercise in RUN/MPG. 
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Question 3) Will the production of NO during exercise trigger the cardioprotective 
effect of 2 days of treadmill exercise in rats? If so, the following changes may 
occur: 
1) Recovery of cardiac function (COxSP), 30 minutes following I/R will be 
greater in RUN vs. SED. This improvement in recovery will be blocked 
by the administration of L-NAME to the animals prior to exercise in 
RUN/-NOS. 
2) The expression of various cardioprotective proteins will increase in RUN 
vs. SED including: HSP70, CAT, MnSOD, iNOS, nNOS, and eNOS. 
These increases in protein expression will be blocked by the 
administration of L-NAME to the animals prior to exercise in RUN/-
NOS. 
Question 4) Will the production of NO by NOS during I/R mediate the 
cardioprotective effect of 2 days of treadmill exercise in rats? If so, the 
following changes may occur: 
1) Recovery of cardiac function (COxSP), 30 minutes following I/R will be 
greater in RUN vs. SED. This improvement in recovery will be blocked 





Animals and training protocols. Male 4-6-month-old Fischer 344 (F-344) rats 
were obtained from the National Institute on Aging (NIA) and kept at the University of 
Texas Animal Resource Center. The animals were maintained on a 12 h:12 h light:dark 
cycle and fed ad libitum with Harlan Teklad 7013, NIH-31 diet. Prior to 
experimentation, rats were randomly assigned to nine different treatment groups: 
sedentary (SED); two days of treadmill exercise (RUN); sedentary / injected with 100 
mg/kg MPG (a potent ROS scavenger) (SED/MPG); exercise / injected with MPG 
(RUN/MPG); sedentary / perfused with 100 µM L-NAME (a competitive inhibitor of 
NOS) (SED/L-N); exercise / perfused with L-NAME (RUN/L-N); exercise in a 4°C 
environment (to prevent HSP70 increase) / perfused with L-NAME (CRUN/L-N); 
sedentary / injected with 50 mg/kg L-NAME (SED/-NOS); exercise / injected with L-
NAME (RUN/-NOS). RUN rats were run on a motorized treadmill (Collins, Braintree, 
MA), at room temperature, for two consecutive days, 60 minutes/day at a speed of 20 
meters/minute up a 6-degree grade. CRUN animals were run on the same motorized 
treadmill with wet fur in an environmental chamber maintained at 4°C, at the same 
intensity and duration as animals run at room temperature. Rectal temperature was 
monitored during the treadmill exercise in both the RUN and CRUN groups with a 
Type J Thermocoupler (no. 600-1000, Barnant, Barrington, IL). Groups receiving 
injections of either MPG or L-NAME received a single intraperitoneal injection of 100 
mg/kg body weight and 50 mg/kg body weight, respectively, 15 minutes prior to each 
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bout of exercise or, in the absence of exercise, 48 and 24 hours prior to evaluation of 
cardiac function. All of the animals were sacrificed 24 hours after their last exercise 
bout or treatment. This investigation, approved by the University’s Animal Care and 
Use Committee (detailed description of animal use in Appendix A), conforms to the 
Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996). 
Isolated heart perfusions. Cardiac function was evaluated using an isolated, 
working heart preparation (119) perfused at 37°C with a modified Krebs-Henseleit 
buffer (preparation detailed in Appendix B) containing (in mM): 10 glucose, 1.75 
CaCl2, 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 24.7 NaHCO3, 0.5 EDTA, 12 mU/mL insulin, 
and gassed with 95% O2-5% CO2. Animals were anesthetized with a single 
intraperitoneal injection of 40 mg/kg body weight of sodium pentobarbital, and 100 IU 
of heparin injected into the inferior vena cava. Once hearts were rapidly excised, they 
were weighed in ice cold saline and mounted on the perfusion apparatus, diagrammed in 
Figure 1. Hearts were initially perfused for 10 minutes in a non-recirculating retrograde, 
or Langendorff, mode at a perfusion pressure of 80 mmHg. After 15 minutes of 
stabilization, hearts were switched to working heart perfusion mode. Working heart 
function was evaluated at an atrial filling pressure of 12.5 mmHg and an afterload set by 
an 80 cm high aortic column (ID 3.18 mm). Groups perfused with L-NAME had solid 
L-NAME (no. N-5751, Sigma Aldrich, St Louis, MO) added to the perfusate prior to 
perfusion resulting in a final concentration of 100 µM. Coronary flow (CF) and aortic 
flow (AF) were determined by timed collection of the effluent dripping off the heart and 
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aortic column overflow, respectively, with cardiac output (CO) determined as the sum 
of CF and AF, and cardiac external work (COxSP) defined as the product of CO and 
peak systolic pressure (SP). All values were normalized for heart wet weight. Aortic 
pressure and heart rate (HR) were monitored through the use of a Gould DTX pressure 
transducer (Gould cardiovascular products, Oxnard, CA) attached to an aortic sidearm. 
The data from the pressure transducer was acquired on a Dell Dimension Desktop 
computer (Dell, Round Rock, TX), and analyzed using Bio Bench data acquisition 
software (National Instruments, Austin, TX). The perfusion/data acquisition system was 
calibrated daily against a known column of perfusate at 0 mmHg and 80 mmHg. Hearts 
were allowed to initially develop their own intrinsic HR; however, if this rate was lower 
than 270 beats/minute, they were electronically paced at 295 beats/minute with an 
electronic stimulator (no. 611, Phipps & Bird Inc., Richmond, VA). During the entire 
perfusion, the coronary effluent was pumped with a peristaltic pump (no. 7553-20, Cole 
Parmer Instrument Company, Chicago, IL) at a constant rate from a enclosed water 
jacketed chamber past a Clark-type oxygen electrode and O2 amplifier (University of 
Pennsylvania Biomedical Instrument Shops, Philadelphia, PA) for the measurement of 
oxygen consumption as described by Starnes et al. (146). The rate of oxygen 
consumption (µmol/min/g heart wet weight) was calculated as: (arterial [O2] – coronary 
effluent [O2]) x rate of coronary flow. Samples of coronary effluent were collected 
every 5 minutes for analysis of lactate dehydrogenase (LDH) content as an indicator of 
sarcolemma damage. After switching from Langendorff to working mode, hearts were 
perfused for 15 minutes prior to cross-clamping both the atrial inflow line and aortic 
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outflow line to induce global ischemia. During ischemia the hearts were enclosed in a 
sealed water-jacketed chamber maintained at 37°C by a Poly Temp heat pump (no. 80, 
Polyscience, Niles, IL), which pumps water through water-jacketed tanks and lines. 
After 22.5 minutes, the aortic inflow was opened and the heart was allowed to recover 
in Langendorff mode for 10 minutes, followed by 20 minutes in the working mode. At 
the end of the perfusion period, the beating hearts were freeze-clamped and stored at     
-80°C until further analysis. Recovery of cardiac function (COxSP) is expressed as the 
percentage of pre-ischemic function (COxSP) recovered 30 minutes following the 
reintroduction of coronary flow post-ischemia. Preliminary studies were carried out to 
determine whether the decline in function following I/R injury was due to the period of 
ischemia and not due to a general decline in function with advancing perfusion time. 
The results of these preliminary studies demonstrate that cardiac function, in the 
absence of ischemia and reperfusion, does not decline during 60 minutes of perfusion 
(Figure 3); therefore, all experimental interventions employed were assessed with 
confidence that any declines in function were due to the ischemic intervention. 
Lactate dehydrogenase Assay. Coronary effluent samples collected every five 
minutes during the perfusion were analyzed for LDH release using a standard kinetics 
assay (13) of the rate of decline in NADH absorbance at 340 nm as lactate is generated 
from pyruvate under non-limiting substrate conditions, detailed in Appendix C. 
Elevated LDH release indicates that the sarcolemma has become damaged and is one of 
the most widely used markers of tissue injury. Although necrosis will certainly result in 
cytosolic enzyme leakage (138, 178), initial occurrence may precede evidence of 
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necrosis (147). Preliminary studies (Figure 4) demonstrated that LDH release does not 
increase following 60 minutes of non-ischemic perfusion. 
Tissue Homogenization. For all assays of enzyme activity and protein content, a 
piece of left ventricle (130-160 mg) was homogenized (1:20 wt/vol) in phosphate buffer 
(50 mM K2HPO4, 0.1 mM EDTA, 0.1% Triton X-100, pH 7.4) using a Teflon-glass 
Potter-Elvehjem homogenizer immersed in an ice bath, detailed in Appendix D. The 
protein concentration of the homogenate was determined by the method of Lowry et al 
(99), detailed in Appendix E. 
Affinity Chromatography. The concentrations of iNOS and nNOS in the whole 
tissue homogenate were too low to detect when directly loaded onto a gel; therefore, 1 
mL of 1:20 tissue homogenate was purified through the use of 2’5’ ADP Sepharose as 
described by Harris et al. (60), detailed in Appendix F. 
SDS-PAGE and Western Blotting. Samples were loaded as described in 
Appendix G, after having been appropriately diluted with Laemmli (88) sample buffer. 
Subsequently, the samples were subjected to SDS-PAGE, detailed in Appendix G, and 
blotted, detailed in Appendix H and I, with the optimized concentrations of antibodies 
for each protein measured, detailed in Appendix J. The content of the various proteins 
measured in the myocardium is reported as a percentage of standard heart homogenate 
loaded on each gel and is adjusted for the protein concentration of the sample 




Catalase and Superoxide Dismutase activity determinations. Homogenates were 
centrifuged at 1,500 X g for 10 minutes at a temperature of 4°C. The supernatant was 
kept on ice and analyzed for catalase activity polarographically within 2 hours using a 
Clark-type oxygen electrode according to Del Rio et al. (41), detailed in Appendix K. 
MnSOD activity was measured spectrophotometrically according to McCord and 
Fridovich (105), detailed in Appendix L. Enzyme assays were run at 25°C. 
Statistical Analysis. Descriptive data (means ± SE) are calculated for each 
dependent variable. For comparisons a factorial analysis of variance (ANOVA) was 
used to test for overall significance, with a Tukey’s HSD test used for post-hoc analysis. 
In all tests, a probability level of <0.05 is used as the decision rule for significance 




 In this study, an animal model was used to represent the metabolic activity of 
humans which limits the applicability of the findings. Factors, such as catecholamine 
release and other metabolic responses to physical stress, may have resulted in changes 
that are not be accounted for in the current study. Cardiac function is measured as the 
product of cardiac output and the peak systolic pressure. These variables may be 
susceptible to measurement error and misrepresentation; however, this product is 
widely accepted as a true measure of hydraulic work and is commonly used in our 
laboratory. During the short period (<2 minutes) after the heart is removed, until it is 
supplied with perfusate, the heart was ischemic and short periods of ischemia may 
provide a cardioprotective effect by preconditioning the heart against a subsequent 
ischemic stress (see (177) for review). However, the heart was kept in ice-cold saline 
during this period of time, which should have minimized any ischemic damage or 
triggers of preconditioning and the hearts of all experimental groups experienced the 
same treatment. Core temperature was measured by insertion of a rectal thermometer. 
This measure of core temperature is not as precise as direct measurement of cardiac 
temperature, but is used as a close approximation. A number of non-physiological 
inhibitors were injected into the animals and included in the perfusate of some of the 
various treatment groups. These inhibitors may have unintended metabolic 
consequences in the myocardium that cannot be accounted for. Additionally, the 
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absorption of these inhibitors into the myocardium may be limited or incomplete, 




 The study was executed with male Fisher-344 rats, 4-6 months old and 
weighing 300-350 g. This limits applicability to humans, but is used as a generalization 





Animal Characteristics. The body weights, heart weights, and ratio of the two 
are reported in Table 1. There were no significant differences among any of the groups 
with respect to body weight or heart weight (P>0.05). The only variation found within 
these variables was in CRUN/L-N, which had a slightly lower body weight/heart weight 
ratio (P<0.05) due to an insignificantly (P>0.05) lower body weight and higher heart 
weight. Although the exercise in the present study is acute, a similar deviation has been 
observed in animals that were chronically run in the cold (61). Although heart weight 
was not increased in the present study to significant levels (P>0.05), and to a lesser 
degree than in the chronic study, similar mechanisms acting over a shorter duration may 
be involved. The cause of the increase is unclear, but could be due to an increase in the 
total peripheral resistance resulting from increased vasoconstriction during exercise in 
the cold as was described by Harris and Starnes (61). This increase was not found in my 
previous study (158), potentially because of the fewer bouts of exercise (1 vs. 2), or to 
differences in core temperature discussed in the following section. 
Core Temperature. The core temperatures of the animals while at rest and 
during exercise (30 and 60 minutes into the bout of exercise) are reported in Table 2. 
The temperature of the RUN animals was significantly (P<0.05) higher than SED rest at 
all time points and was significantly (P<0.05) lower at all time points in CRUN/L-N. 
The lower temperature in CRUN/L-N was not expected to be lower than SED rest and 
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although this may have affected the body weight/heart weight ratio, it does not appear 
to have affected the functional results, as discussed in following sections. 
QUESTION 1 – UNCOUPLING AS A MEDIATOR 
Cardiac Function. No significant differences in cardiac efficiency 
(COxSP/oxygen consumption) were observed in any group prior to ischemia (P>0.05); 
however, efficiency was higher in RUN vs. SED at all time points following ischemia 
(Figure 5). 
UCP2 Expression. The concentration of UCP2 in the whole heart homogenate 
was too low to detect by western blotting (data not shown). 
QUESTION 2 – ROS AS A TRIGGER 
 Cardiac Function. Hemodynamic parameters prior to and 30 minutes following 
ischemia are displayed in Table 3. Prior to ischemia, cardiac function (COxSP) (Figure 
6) was similar in all groups except SED/MPG, which was 15.0% higher than 
RUN/MPG; therefore, COxSP following ischemia was evaluated as a percentage of the 
pre-ischemic function (Figure 7). Following ischemia, RUN recovered a greater 
percentage of pre-ischemic function than SED (P<0.05), MPG alone did not affect 
recovery (SED vs. SED/MPG, P>0.05), and MPG did not block the preconditioning 
effects of exercise (RUN vs. RUN/MPG, P>0.05). No differences in cardiac efficiency 
were observed prior to ischemia (P>0.05) and although efficiency tended to be higher in 
RUN and RUN/MPG following ischemia, only RUN reached the (P<0.05) level of 
significance at 20 minutes post-ischemia (data not shown). Release of LDH (Figure 8) 
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was not different in any group prior to ischemia (P>0.05) and increased in all groups 5, 
10, and 15 minutes following ischemia (P<0.05). The magnitude of the increase was 
greatest at 10 minutes post-ischemia, and training status was more important in 
reducing sarcolemma damage as MPG injection did not significantly (P>0.05) affect 
LDH release (SED vs. SED/MPG, RUN vs. RUN/MPG), while at 10 and 15 minutes 
post-ischemia LDH release was greater in SED vs. RUN (P<0.05). 
 Tissue Analysis. Expression of HSP70 in the left ventricle (Figure 9) increased 
in RUN vs. SED (P<0.05), was not affected by MPG alone (SED vs. SED/MPG, 
P>0.05), and was not blocked by administration of MPG (RUN vs. RUN/MPG, 
P>0.05). No significant changes in the expression of iNOS (Figure 10) or eNOS (Figure 
11) were detected in any group (P>0.05), and nNOS expression could not be detected 
any experimental sample. This may be due to species-specific differences in expression, 
as nNOS could be detected in the myocardium of Sprague Dawley rats, but not in 
samples from the F-344 rats used in the present study (Figure 12). The activity of CAT 
(Figure 13) increased in groups SED/MPG and RUN/MPG vs. SED and RUN (P<0.05), 
which suggests that MPG alone induced an increase in CAT; however, this increase in 
CAT did not affect tolerance to I/R injury (Figure 7). No changes in MnSOD activity 
(Figure 14) were observed in any group (P>0.05). 
QUESTION 3 – NO AS A TRIGGER 
 This question was not able to be addressed, as the animals were not able to 
perform the exercise after receiving injections of L-NAME. The reasons for this 
observed phenomenon are discussed in detail in the following sections. 
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QUESTION 4 – NO AS A MEDIATOR 
 Cardiac Function. Hemodynamic parameters prior to and 30 minutes following 
ischemia are displayed in Table 3. Of these parameters the most important observation 
is that perfusion with L-NAME decreased CF (SED pre vs. SED/ L-N pre, RUN pre vs. 
RUN/L-N pre, P<0.05), suggesting that NOS was effectively inhibited. Prior to 
ischemia, cardiac function (COxSP) (Figure 15) was not different between any group 
(P>0.05). Thirty minutes following ischemia, RUN recovered a greater percentage of 
pre-ischemic function than SED (P<0.05), L-NAME alone did not affect recovery (SED 
vs. SED/L-N, P>0.05), and L-NAME did not block the preconditioning effects of 
exercise in the ambient temperature (RUN vs. RUN/L-N, P>0.05) or in the cold (RUN 
vs. CRUN/L-N, P>0.05). No differences in cardiac efficiency (Figure 16) were 
observed prior to ischemia (P>0.05). Following ischemia, at all time points, all exercise 
groups (RUN, RUN/L-N, and CRUN/L-N) displayed greater efficiency (P<0.05) than 
both sedentary groups (SED and SED/L-N), which was not affected by L-NAME under 
any circumstances. Release of LDH (Figure 17) was not different in any group prior to 
ischemia (P>0.05) and increased in all groups, except CRUN/L-N, 5 and 10 minutes 
following ischemia (P<0.05). The magnitude of the increase was greatest at 10 minutes 
post-ischemia, while exercise in ambient or cold temperature reduced release in all 
groups and was not increased by L-NAME (RUN, RUN/L-N, and CRUN/L-N vs. SED, 
P<0.05). Perfusion with L-NAME alone appears to protect against sarcolemma damage 
as LDH release was reduced in SED/L-N vs. SED (P<0.05), but this protective effect 
was not manifested into greater functional recovery (Figure 15). 
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Tissue Analysis. Expression of HSP70 in the left ventricle (Figure 18) increased 
in RUN vs. SED (P<0.05), and was not affected by administration of L-NAME (SED 
vs. SED/L-N; RUN vs. RUN/L-N and CRUN/L-N, P>0.05). No significant changes in 
the expression of iNOS (Figure 19) were observed (P>0.05) and eNOS (Figure 20) was 
elevated in CRUN/L-N vs. all other groups (P<0.05), which may explain the increased 
CF observed in my previous study (158), but does not appear to be the primary mediator 
of the cardioprotection observed as L-NAME did not block the cardioprotective effect 
of acute exercise in the cold (Figure 15). No changes in CAT (Figure 21) were observed 
in any groups (P>0.05); however, MnSOD (Figure 22) decreased in CRUN/L-N vs. 





 The preliminary studies that led to the initiation of these experiments (158) 
demonstrated that acute exercise-induced cardioprotection could be acquired without 
increasing HSP70, which was previously thought to mediate the improved tolerance to 
ischemia reperfusion injury (98). The present study represents the investigation of a 
number of other potential triggers and mediators of acute exercise-induced 
cardioprotection, including ROS and NO, that have been implicated in heat-stress and 
ischemic preconditioning. As will be discussed below, there appear to be numerous 
similarities in how the various forms of preconditioning manifest into cardioprotective 
phenotypes; however, the results of our experiments suggest that important differences 
exist between acute exercise preconditioning and those from heat-stress or ischemic 
preconditioning. 
QUESTION 1 – UNCOUPLING AS A MEDIATOR 
 Induction of an uncoupling effect following acute exercise appears to be 
counterintuitive, as one would expect that exercise would induce changes increasing the 
efficiency of myocardial hydraulic work; however, non-physiological uncouplers 
clearly do protect against I/R injury (111). If acute exercise were to induce these 
changes, cardiac efficiency should be expected to decrease both before and after, or 
potentially only after ischemia if the activity of the uncoupling protein were to be 
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activated by increased production of ROS and/or other stresses. Prior to the present 
investigation none of these variables had been evaluated following acute exercise. The 
following results suggest that uncoupling does not mediate acute exercise-induced 
preconditioning. 
In the present study, cardiac efficiency prior to ischemia was similar in all 
groups; however, throughout the post-ischemic recovery period hearts of animals run in 
either the ambient temperature or in the cold functioned much more efficiently than 
hearts of sedentary animals (Figures 5 and 16). If uncoupling of oxygen consumption 
from ATP production occurred in any animals, it was the sedentary groups whose post-
ischemic recovery of mechanical function was considerably less than that of the 
runners. In the SED group, post-ischemic function decreased 49.7% compared to the 
pre-ischemic value, but oxygen consumption only declined 15.6%. Therefore, the 
greater proportional decrease in function as compared to oxygen consumption in SED 
resulted in the lower ratio of cardiac efficiency. 
Although the effects of L-NAME will be discussed in greater detail in following 
sections, it should be noted that L-NAME in the perfusate did not affect myocardial 
oxygen consumption or efficiency (Figure 16) in spite of a significant decrease in CF in 
SED/L-N vs. SED (Table 3). Normally CF will increase/decrease in direct proportion to 
the oxygen demands of the myocardium. In the isolated, buffer perfused, working rat 
heart, the oxygen concentration in the coronary flow effluent is relatively high 
(approximately 325 µM), providing for considerable O2 reserve to allow for increased 
O2 extraction when CF rate is reduced by NOS inhibition. It was observed that when L-
 
43
NAME was present in the perfusate, O2 extraction increased in proportion to the 
decrease in CF and the O2 concentration in the coronary effluent dropped to 
approximately 175 µM. It is unlikely that this much flexibility in CF and O2 extraction 
exists in-vivo where the baseline CF rate is much lower and O2 in the blood is bound to 
hemoglobin. The kinetics of oxygen extraction in the hemoglobin-free perfusion buffer 
is not limited by the oxygen saturation characteristics and carrying capacity of 
hemoglobin. 
The western blotting experiments, initiated in order to detect changes in UCP2 
expression following the various exercise protocols and interventions, did not yield any 
reliable results due to the fact that the concentration of the protein was too low to detect 
in whole heart homogenate samples. Knowing that the site of action for UCP2 is the 
mitochondria, it is possible that the protein could have been detected in samples of 
isolated mitochondria; however, the hearts had already been frozen, thereby prohibiting 
the isolation of the mitochondria. Recently, another group of investigators have reported 
that they were able to detect UCP2 protein in mitochondria isolated from cardiac tissue 
(106). The authors provide substantial evidence that ischemic preconditioning, which 
provides a preconditioning effect in the myocardium against I/R injury, was capable of 
increasing the expression of UCP2 two-fold and that this increase was primarily 
responsible for mediating their observed cardioprotection. These data would appear to 
conflict with the findings of the present study and this is the first of many differences to 
be contrasted in this discussion regarding acute exercise-induced vs. other 
preconditioning stimuli. However, due to the fact that cardiac efficiency was not 
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decreased, but rather increased, in all exercising groups, it is not likely that uncoupling 
serves to mediate acute exercise-induced preconditioning. 
QUESTION 2 – ROS AS A TRIGGER 
 The results presented herein suggest that quenching ROS during exercise does 
not block the trigger that initiates the adaptations leading to acute exercise-induced 
cardioprotection. This is represented by the inability of MPG administration during two 
days of exercise to decrease the amount of post-ischemic functional recovery compared 
to exercise without MPG administration (RUN/MPG vs. RUN) (Figure 7). The 
administration of exogenous MPG as a radical scavenger has been used in experimental 
studies for many decades now (19, 45, 112, 113, 133, 141), and the dosage of 100 
mg/kg selected for the present study is known to block the triggering stimuli of both 
heat-stress (2, 174) and ischemic (156, 160) preconditioning. One other group of 
investigators (173) reported that 100 mg/kg MPG administration during a single 20-
minute exercise bout prevents acute exercise-induced cardioprotection, 48 hours 
following cessation of exercise, against infarct development following coronary artery 
occlusion in vivo. They propose that the acute exercise-induced cardioprotection is due 
to increased MnSOD (67% increase 48 hours after exercise) and they report that MPG 
prevented up-regulation of this antioxidant enzyme. It should be noted that no other 
studies have reported such a dramatic change in MnSOD even when the exercise bout is 
longer and more intense. The differences between the results of Yamashita et al. (173) 
and those presented herein could be due to either the strain of animal (Wistar), the 
indices of myocardial dysfunction used (infarct size), or to the short duration of exercise 
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(20 minutes). In any case, this same group of investigators regularly report results that 
differ than those of many other investigators; therefore, the work discussed herein 
should help to clarify the effect of MPG upon acute exercise-induced cardioprotection. 
Prior work with this dosage of MPG has established that it may result in mild liver 
damage (133). For this reason, and due to the fact that the 100 mg/kg dosage has been 
effective against several forms of preconditioning, it would not be reasonable to assume 
that the dosage could have been further increased in order to augment the scavenging 
capacity. 
Included among the many functional parameters listed in Table 3 is that 10-12 
rats were perfused in answering the question regarding ROS as a trigger (SED/MPG 
and RUN/MPG), while only 6-7 rats were required to reach significance in all other 
experimental groups. The reason for the additional MPG animals was that a high 
variability in the absolute values of post-ischemic function was observed in these 
groups. We subsequently realized that the variability during post-ischemia was due to 
slight differences in the pre-ischemic COxSP in these two groups. When the COxSP 
values for SED/MPG and RUN/MPG were scrutinized, the observation was made that 
the variations in post ischemic values paralleled those of the pre-ischemic on a 
reasonably individual basis, thus it appeared that there was a degree of covariance 
between the pre- and post-ischemic variables. When the post-ischemic recovery was 
expressed as a percentage of pre-ischemic function in each heart, the variability 
decreased and it became apparent that MPG administration did not prevent improved 
acute exercise-induced cardioprotection. The results for LDH release (Figure 8), which 
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show no main effect of MPG, only serve to validate the present interpretation of the 
functional results. Therefore, the sum of the observations, including the additional data 
points for the functional data and the LDH results, increases confidence in the 
conclusion that MPG did not inhibit the triggering response of acute exercise and that 
MPG did not induce a protective effect in sedentary animals. 
The reason for the MPG-related alterations in pre-ischemic COxSP is not clear; 
however, initial measurements of enzymatic activity suggested that injection of MPG 
was causing some other unusual adaptations, including an increase in CAT activity 
independent of training status (Figure 13). The rationalization initially proposed as an 
explanation for the increased catalase activity was that there was residual MPG in the 
myocardial tissue and it was somehow affecting the measurement of CAT. This 
explanation was dismissed by adding MPG directly to the reaction vessel during 
analysis to observe its affect on the measurement of CAT in an untreated sample. No 
changes in the assay rate were observed with added MPG (data not shown), which 
agrees with earlier reports that MPG does not affect H2O2 metabolism (19). The 
mechanism for increased CAT activity is not apparent; however, a similar response has 
been observed in hepatic tissue (52), but not in cardiac tissue with chronic 
administration/training (40). It is important to note that administration of MPG did not 
have the effect of inhibiting or increasing any of the other cardioprotective proteins, 
including the increase in HSP70 due to two days of running (Figure 9). 
Although no other differences in protein expression resulted from MPG 
administration, an unexpected species-specific variation was inadvertently discovered. 
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Blotting for nNOS initially was not providing any results; however, it was noticed that a 
band was appearing at the appropriate molecular weight in the lane corresponding to the 
standard that was loaded. After checking the records regarding the standard, a 
realization was made that the standard was composed of a pooled homogenate from 
Sprague Dawley rats vs. F344 used in the present study. A qualitative comparison of 
nNOS expression between Sprague Dawley and F344 rats (Figure 12) shows that the 
expression of nNOS in sedentary animals is much lower in F344 and is not up-regulated 
in response to acute exercise. The levels of protein were too low to quantify and; 
therefore, are not statistically analyzed. nNOS does not appear to have a significant role 
in the myocardium of F344 rats, but the differences described herein could explain 
some of the differences reported in the literature regarding NOS. 
QUESTION 3 – NO AS A TRIGGER 
 As stated in the results section, this question was not able to be addressed, as the 
rats were not able to complete the exercise bout. Specifically, following the initiation of 
exercise, the rats could not run more than ~10 minutes before requiring excessive use of 
a motivational stimulus. It was determined, after consulting with my supervising 
professor, that continuation of the exercise protocol would be inhumane. The options 
available for adapting our treatment protocol were discussed including: decreasing the 
amount of exercise time and/or the concentration of L-NAME administered. With 
regards to the duration of exercise, it was decided that decreasing the amount of running 
time was not a viable option. If a decreased tolerance to I/R following two shorter bouts 
of exercise were observed, it would not be clear if the observed effects were due to 
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inhibition of the triggering stimuli by L-NAME, or simply a lack of a stimulus of a 
sufficient magnitude to trigger cardioprotection. 
 It has been reported that L-NAME can be administered prior to treadmill 
exercise in rats, but the dosages used to date are well below what is required for 
complete inhibition of NOS. For example, Musch et al. (118) and Husain (67) used a 
dose of 10 mg/kg, which is 5 times lower than the dose used in the present study. This 
dosage would be approximately equivalent to a concentration of 37 µM (10 mg / 269.7 
g/mol), assuming that it was absorbed into all tissues proportionally. However this does 
not happen, as muscle tissue accounts for approximately 50% of the total mass of the 
body, and even if the assumption was made that L-NAME were to distribute evenly 
throughout all muscle, the final concentration would be maximally 74 µM, ignoring 
degradation and absorption into other tissues. These two concentrations are 63% and 
26% respectively, below what is minimally required (100 µM) for complete inhibition 
of NOS (126). It has been confirmed experimentally that 4 mg/kg of L-NAME results in 
a final skeletal muscle concentration of 38 µmol per kg of dry weight in humans, which 
corresponds to a measured wet tissue concentration of 10 µM (55). The authors report 
that this concentration will inhibit 67% of NOS activity, measured in extracted tissue 
samples from human skeletal muscle, when the conversion of arginine to citrulline was 
assayed. Assuming a linearity of increasing muscle concentration with increasing 
dosage, the rats from the first two studies (67, 118) would have a maximal tissue 
concentration of 25 µM (well below the inhibitory threshold of 100 µM) and the rats 
from the experiments proposed for the present study would have a maximal tissue 
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concentration of 125 µM (above 100 µM). Therefore, if the concentration of L-NAME 
were decreased in the present study, to a level permitting completion of the exercise 
protocol, NOS would not be completely inhibited and the triggering response, if it 
occurs through this pathway, would be only partially inhibited. If production of NO by 
NOS is responsible for triggering acute-exercise induced preconditioning, any 
cardioprotective effects may not be abrogated. 
 The underlying reason for the inability of the rats to perform extended treadmill 
exercise may be because of a decrease in either skeletal or myocardial muscle blood 
flow or a combination of both. During exercise, the oxygen demands of both cardiac 
and skeletal muscle increase in response to the greater rates of energy utilization. If the 
normal maximal capacity for oxygen to be delivered is attenuated, then the maximum 
rate of energy utilization, i.e. rate of exercise, will also be decreased. The dosage of L-
NAME used in the present study (50 mg/kg) should not have affected resting 
myocardial CF or myocardial function as 30 mg/kg has been previously reported to 
have no effect, while 300 mg/kg can affect resting values (37). L-NAME, in dosages of 
1-10 mg/kg, decreases myocardial oxygen uptake (139), while other studies have 
observed either no effect upon oxygen uptake in skeletal muscle with similar 
concentrations (55) or alternatively decreases in skeletal muscle vascular conductance 
(118). Other studies that provide data supporting a decreased exercise capacity due to 
NO alterations include: a decreased voluntary exercise response in mice with NOS 
knocked-out (115) and a decreased exercise capacity in humans with decreased NO 
production following heart transplant (136). The collective conclusion derived from 
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these studies is that in order for a rat to exercise at an intensity and duration demanded 
in the present study, adequate NO production and muscle blood flow is required. 
Unfortunately, the present study does not provide an answer to the question as to 
whether or not NO serves as a trigger of acute-exercise induced preconditioning. In 
order for this question to be answered in the future, the cellular targets involved with the 
vasodilatory effects of NO will need to be separated from those which initiate pathways 
of preconditioning. In the review of literature, it is stated that nitrosylation of PKCε has 
been proposed as a primary target for activation of the preconditioning response (7, 
153). If this signaling event could be blocked either by specifically inhibiting the 
actions of NO at this site of activation or by mutating the activation site on this 
signaling protein, thereby preventing activation, the relative contribution of NO to the 
triggering response of acute exercise could be elucidated. Clearly, additional work will 
be required to fully address this question, which lies beyond the scope of the present 
investigation. 
QUESTION 4 – NO AS A MEDIATOR 
 Although NO has the ability to trigger preconditioning, it can also mediate 
cardioprotection (17); however, the results of this study suggest that it is not a mediator 
of acute exercise-induced cardioprotection against myocardial stunning. The 
observation that CF increased in the group of animals run in a cold environment (158) 
initiated the investigation of NOS as a potential mediator of acute exercise-induced 
cardioprotection; however, both the functional results and the protein expression 
patterns of the present study suggest that NOS is not a mediator of acute exercise-
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induced preconditioning. L-NAME, at a concentration of 100 µM, which did not affect 
the pre-ischemic function of any group, was included in the perfusate both before and 
after ischemia (Figure 15). Following ischemia, both exercise groups receiving L-
NAME recovered similarly to the exercised animals not receiving it and better than the 
two sedentary groups. These results suggest that NOS, irregardless of isoform, does not 
mediate acute exercise-induced cardioprotection. L-NAME did result in a decreased 
LDH release following ischemia, but this may be due to inhibition of the constitutive 
expression of NOS, as L-NAME decreased release in sedentary animals, SED/L-N vs. 
SED (Figure 17). 
 The absence of an abrogating effect of L-NAME is more than likely due to 
cardioprotective effects of other protective proteins not identified in this investigation, 
rather than an insufficient inhibition of NOS. The concentration of L-NAME (100 µM) 
used in the perfusate is the concentration required for 100% inhibition of NOS (126) 
and equivalent or lower concentrations have successfully inhibited the effects of 
ischemic (20, 131) and heat-stress (1, 74) preconditioning. Other reports show that the 
skeletal muscle concentration of L-NAME should exceed 100 µM (and the assumption 
can be made that a similar response occurs in myocardial tissue) when perfused with 
100 µM (55). 
 The most interesting protein change to occur in this study is the increase in 
eNOS in CRUN/L-N (Figure 20). Although this increase in NOS did not mediate the 
cardioprotective effect of running in the cold, illustrated by the fact that L-NAME was 
not able to block the improved recovery following acute exercise, it may explain the 
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increased CF observed in the preliminary study that initiated this series of experiments 
(158). Further evidence that eNOS was responsible for the previously observed increase 
in CF is that L-NAME prevented a similar post-ischemic increase in CF in the present 
study (CRUN/L-N, Table 3).  
 The findings presented herein have a number of differences from those reported 
by Babai et al. (4) who found that the iNOS-specific inhibitor, aminoguanidine, blocked 
the preconditioning effects of a single, 21-minute, bout of exercise in dogs. They also 
found that the activity of iNOS increased 3-fold in the myocardium 24 hours following 
exercise. The reason for these differences from the present study could be that species-
specific variations result in differential expression of iNOS, as similarly there are 
clearly differences in expression of nNOS in F344 rats compared to Sprague Dawley 
rats (Figure 12). However, a more plausible explanation can be found in how tolerance 
to coronary occlusion and NOS expression were evaluated. The authors report that 
aminoguanidine reduced survivability from coronary occlusion in exercised animals, 
but this same dosage of aminoguanidine also reduced survivability to 0% in sedentary 
animals. This suggests that aminoguanidine alone had a significant effect of lowering 
tolerance to coronary occlusion rather than blocking a protective effect. Conversely, in 
our isolated rat hearts subjected to I/R, functional recovery was not affected by L-
NAME and release of LDH (an indicator of sarcolemmal damage) was decreased. The 
reason for these differences is not completely clear. Babai et al. detected iNOS by the 
highly variable assay of measuring the activity of the enzyme as arginine is converted to 
citrulline, rather than by western blotting or ELISA. Even in studies of heat-stress and 
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ischemic preconditioning, increases in iNOS are small in magnitude (17), which 
contrasts with the greater than three-fold increase reported by the authors; therefore, it is 
unclear whether or not the results can be confidently accepted. 
The results of the present study represent a divergence from the reports that 
inhibitors of NOS are capable of blocking heat-stress, ischemic, and even acute 
exercise-induced myocardial preconditioning. Although eNOS was increased in the 
animals that ran in the cold, it was not responsible for mediating the protection 
provided. One of the primary differences between the results of this study and others is 
that iNOS did not increase under any circumstances. This could be due to the fact that 
the magnitude of the change was too small to detect via western blotting. However, 
even if there were changes that went undetected, L-NAME did not block any protective 
effects. Therefore, NOS is not a likely mediator of acute exercise-induced 
cardioprotection, and it is still not clear as to what might be the responsible for the 
protective effect observed herein. Adaptation to exercise is a very complex process, and 
depending upon the mode, duration, and intensity; different adaptations may occur. It is 
clear that many different proven cardioprotective proteins can be up-regulated following 
exercise, and the cardioprotective response may be a cumulative effect of known and 
unknown proteins/mechanisms, which cannot be inhibited on an individual, or even on 
a multiple basis as demonstrated when HSP70 was blocked by exercise in the cold and 




When considered together, the results of the present study suggest that acute 
exercise-induced cardioprotection is not triggered by ROS production and is mediated 
by factors other than NOS and mitochondrial uncoupling. It is still not clear as to 
whether or not NO is responsible for triggering the cardioprotective effect of acute 
exercise; however, when the observation that NO production is necessary for 
performing exercise is considered together with the abundance of data supporting the 
role of NO to trigger a preconditioning response, it is not difficult to imagine that NO 
could be a trigger of acute exercise-induced preconditioning. Along with the described 
functional changes, increases in various cardioprotective proteins did occur; however, it 
is still not evident what the cumulative effects of these are and clearly there could be 
other cardioprotective proteins, and related changes in expression and activation, yet to 
be identified. 
Although the various interventions employed did not abrogate either the triggers 
or mediators of acute exercise-induced cardioprotection, these results serve to exclude a 
number of proposed mechanisms. Moreover, the preconceived notion that the nature of 
the preconditioning repose of the myocardium to varying stimuli is uniform has been 
thoroughly invalidated. Although heat-stress and ischemic preconditioning may provide 
clues as to the mechanisms underlying the observed protection resulting from acute 
exercise, they do not mimic the influence of exercise exactly. Hopefully, future 
investigations will be able to further elucidate the mechanisms of acute exercise-
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TABLE 1 – ANIMAL CHARACTERISTICS 
 n Body Weight 
(g) 
Heart Weight (mg) Ratio (g/mg) 
SED 7 336.6 ± 9.3 921 ± 25 0.366 ± 0.006 
RUN 7 328.0 ± 9.6 957 ± 9 0.343 ± 0.007 
SED/MPG 12 346.7 ± 4.8 918 ± 12 0.378 ± 0.005 
RUN/MPG 10 341.2 ± 4.5 972 ± 16 0.352 ± 0.005 
SED/L-N 6 345.0 ± 8.3 933 ± 14 0.370 ± 0.008 
RUN/L-N 6 306.7 ± 3.5 905 ± 11 0.339 ± 0.003 
CRUN/L-N 7 323.1 ± 10.2 990 ± 34 0.327 ± 0.004 * 
Values are mean ± SE; n, number of rats. *(P<0.05) vs. SED. 
TABLE 2 – CORE TEMPERATURE, PRIOR TO AND DURING EXERCISE 
 Rest 30 minutes 60 minutes 
SED 37.7 ± 0.1   
RUN  40.6 ± 0.1 * 41.2 ± 0.2 * 
CRUN/L-N  36.2 ± 0.4 * 34.3 ± 0.6 * 
Values are mean ± SE, n = 5-6. Core temperature represents rectal temperature at listed 
time point. *(P<0.05) vs. SED Rest. 
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SED 13.5 ± 0.5 41.3 ± 2.6 54.8 ± 2.9 114.1 ± 2.4 277 ± 9 
RUN 14.2 ± 0.6 45.6 ± 1.9 59.8 ± 2.4 111.0 ± 1.4 300 ± 5 * 
SED/MPG 15.4 ± 0.7 48.0 ± 1.7 63.4 ± 2.0 * 110.8 ± 1.7 291 ± 4 
RUN/MPG 13.5 ± 0.5 42.7 ± 1.2 56.2 ± 1.6 108.8 ± 1.5 287 ± 5 
SED/L-N 10.9 ± 0.6 * 44.1 ± 2.0 55.1 ± 2.4 108.5 ± 3.4 284 ± 6 
RUN/L-N 11.9 ± 0.4 49.2 ± 1.2 61.0 ± 1.5 111.2 ± 1.1 298 ± 4 
CRUN/L-N 12.4 ± 0.3 46.4 ± 1.2 58.8 ± 1.4 114.4 ± 1.8 295 ± 0 
30 Minutes Post-Ischemia 
SED 11.7 ± 0.7 19.2 ± 2.8 † 30.9 ± 2.9 † 101.3 ± 2.7 † 262 ± 13 
RUN 14.2 ± 0.8 * 33.4 ± 2.7 *† 47.7 ± 3.4 * 109.1 ± 1.4 298 ± 4 
SED/MPG 14.4 ± 1.0 23.7 ± 4.1 † 38.0 ± 4.4 † 99.6 ± 1.5 † 266 ± 13 
RUN/MPG 13.9 ± 0.5 31.5 ± 2.5 45.4 ± 2.7 102.8 ± 1.8 285 ± 6 
SED/L-N 8.7 ± 0.4 *† 19.1 ± 4.7 † 27.8 ± 5.0 † 95.3 ± 4.5 248 ± 17 
RUN/L-N 11.4 ± 0.6 37.7 ± 1.8 *† 49.0 ± 2.2 *† 106.8 ± 1.5 296 ± 2 
CRUN/L-N 11.7 ± 0.4 37.5 ± 1.6 *† 49.2 ± 1.4 *† 113.7 ± 1.7 * 295 ± 0 
Values are mean ± SE. CF, coronary flow; AF, aortic flow; CO, cardiac output; SP 































































































Cardiac function (COxSP) over time, in the absence of ischemia. Values are mean ± SE, 
n=6. *(P<0.05) vs. 15 minutes. 
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Lactate dehydrogenase (LDH) release in the coronary effluent over time, in the absence 
of ischemia. Values are mean ± SE, n=6. *(P<0.05) vs. 10 minutes. 
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Cardiac efficiency (COxSP/oxygen consumption). Values are mean ± SE. *(P<0.05) 














































Cardiac function (COxSP), expressed as mmHG x mL/min/g heart wet weight. Values 
are mean ± SE. *(P<0.05) SED/MPG vs. RUN/MPG, †(P<0.05) SED vs. RUN, 
‡(P<0.05) SED vs. RUN/MPG. 
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Cardiac function (COxSP), expressed as a percentage of pre-ischemic value. Values are 











































Lactate dehydrogenase (LDH) release in the coronary effluent. Values are mean ± SE. 
All groups are increased from pre-ischemic values 5, 10, and 15 minutes following 
ischemia (P<0.05). *(P<0.05) SED vs. RUN/MPG, †(P<0.05) SED/MPG vs. 
RUN/MPG; ‡(P<0.05) SED vs. RUN. 
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Heat shock protein 70 (HSP70) content of the left ventricle (LV), expressed as a 
percentage of a standard solution of HSP70. Values are mean ± SE. *(P<0.05) RUN and 
RUN/MPG vs. SED and SED/MPG. Representative scan of western blot below figure. 
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Inducible nitric oxide synthase (iNOS) content of the left ventricle (LV), expressed as a 
percentage of a standard solution of iNOS. Values are mean ± SE. No significant 
differences (P>0.05). Representative scan of western blot below figure. 
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Endothelial nitric oxide synthase (eNOS) content of the left ventricle (LV), expressed as 
a percentage of a standard solution of eNOS. Values are mean ± SE. No significant 
differences (P>0.05). Representative scan of western blot below figure. 
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FIGURE 12 – NNOS EXPRESSION 
 
Comparison of neuronal nitric oxide synthase (nNOS) expression in the left ventricle of 
Sprague Dawley (SD) and Fischer 344 (F344) rats. 
 
70

























Enzymatic activity of catalase (CAT) in the left ventricle (LV), expressed as Units 
CAT/mg heart wet weight, where 1 Unit = 1 µmol H2O2/min. Values are mean ± SE. 
*(P<0.05) SED/MPG and RUN/MPG vs. SED and RUN. 
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Enzymatic activity of manganese superoxide dismutase (MnSOD) in the left ventricle 
(LV), expressed as Units MnSOD/mg heart wet weight, where 1 unit = 50% inhibition 
of baseline. Values are mean ± SE. No significant differences (P>0.05). 
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Cardiac function (COxSP), expressed as mmHG x mL/min/g heart wet weight. Values 
are mean ± SE. *(P<0.05) RUN, RUN/L-N and CRUN/L-N vs. SED and SED/L-N. 
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* * * *
 
Cardiac efficiency (COxSP/oxygen consumption). Values are mean ± SE. *(P<0.05) 
RUN, RUN/L-N, and CRUN/L-N vs. SED and SED/L-N. 
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Lactate dehydrogenase (LDH) release in the coronary effluent. Values are mean ± SE. 
Groups SED/L-N and RUN/L-N increased from pre-ischemic values 5 and 10 minutes 
following ischemia (P<0.05) and no significant (P>0.05) increases were observed at any 
time point for CRUN/L-N. *(P<0.05) SED vs. RUN/L-N, †(P<0.05) SED vs. CRUN/L-
N, ‡(P<0.05) SED vs. RUN, #(P<0.05) SED vs. SED/L-N. 
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Heat shock protein 70 (HSP70) content of the left ventricle (LV), expressed as a 
percentage of a standard solution of HSP70. Values are mean ± SE. *(P<0.05) RUN vs. 
SED and CRUN/L-N. Representative scan of western blot below figure. 
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Inducible nitric oxide synthase (iNOS) content of the left ventricle (LV), expressed as a 
percentage of a standard solution of iNOS. Values are mean ± SE. No significant 
differences (P>0.05). Representative scan of western blot below figure. 
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Endothelial nitric oxide synthase (eNOS) content of the left ventricle (LV), expressed as 
a percentage of a standard solution of eNOS. Values are mean ± SE. *(P<0.05) 






























Enzymatic activity of catalase (CAT) in the left ventricle (LV), expressed as Units/mg 
heart wet weight, where 1 Unit = 1 µmol H2O2/min. Values are mean ± SE. No 
significant differences (P>0.05). 
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Enzymatic activity of manganese superoxide dismutase (MnSOD) in the left ventricle 
(LV), expressed as Units MnSOD/mg heart wet weight, where 1 unit = 50% inhibition 




 APPENDIX A- ANIMAL USE 
1. Description of use. During the duration of this project, approximately 90 
animals were utilized. Animals were purchased at 3 months of age and evaluated 
approximately 1-2 months after arrival. On the day of the experiment, rats were 
transported to the animal vivarium and environmental chamber located in Rm. 
330, Bellmont Hall. 24 hours following experimental treatment, including 
treadmill running and/or intraperitoneal injection of physiological inhibitors, the 
rats were transported to the laboratory of Dr. J. W. Starnes located in Rm. 822A, 
Bellmont Hall. In Dr. Starnes' lab the animals were anesthetized with an 
intraperitoneal injection of sodium pentobarbital at 40 mg/kg body weight, 
which will prevented any conscious response during surgery. The heart was then 
excised from the anesthetized animal and all experiments carried out on the 
isolated heart. 
2. Justification of use. I have demonstrated that exercise training results in better 
recovery of myocardial contractile pump function following ischemia and 
subsequent reperfusion. This exercise-induced beneficial adaptation may be at 
least partially responsible for the increased survivability of heart attacks reported 
in physically active humans and the decreased risk of having a heart attack 
during physical activity in people who regularly exercise. This exercise-induced 
beneficial adaptation may also include protection against oxidative stress. The 
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overall specific aim of this research project was to determine the role of certain 
protective proteins in the attenuation of ischemia-reperfusion injury and 
protection against oxidative stress in the myocardium of acute exercise-trained 
rats. Finding ways to protect the heart during ischemic episodes is important as 
the occurrence of these episodes may lead to myocardial infarction, which is the 
leading cause of death in the United States. Human subjects are inappropriate 
because the end-point of the experiments requires that the heart be damaged. 
Non-animal species are inappropriate because they do not have a heart that is 
similar to that of a human. The rat is deemed most appropriate because of the 
prior studies carried out on this specie, ease of handling, and expense. 
3. Information on veterinary care. Animals were housed in a central animal care 
facility under the direction of veterinarian specializing in laboratory animals. 
The University of Texas at Austin has an animal welfare assurance letter on file 
with NIH (#A 1496). 
4. Procedures for ensuring that discomfort, distress, pain and injury are limited 
and the use of anesthetic drugs. There is modest risk of injury while exercising 
on the rodent treadmill. This risk was minimized by first acclimatizing the rats 
to the treadmill at sub-maximum intensities so that stress and fatigue was not a 
factor. If a rat refused to run, it was removed from the study. The only injury 
experienced by a rat was a cut toenail, and the animal was removed from the 
treadmill and antibiotic cream was administered to the toe area. The rats were 
anesthetized with sodium pentobarbital at a dosage of 40 mg/kg body weight, 
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administered intraperitoneally by Ryan Taylor who has been trained in this 
procedure by Dr. Joseph Starnes, who has been routinely carrying out this 
procedure since 1976. 
5. Method of euthanasia. Removing the heart from the anesthetized animal 
produced a euthanizing effect. This method is consistent with the 
recommendations of the Panel on Euthanasia of the American Veterinary 
Medical Association. Dead animals were placed in the morgue located at the 
Animal Resources Center. 
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APPENDIX B- KREBS-HENSELEIT BUFFER 
Solutions: 
3.85 M NaCl (58.4 g/mol) (Sigma # S-9625) + 
0.325 M Glucose (180.2 g/mol) (Sigma # G-8270): 
  For 1000 mL 
   224.8 g NaCl + 58.6 g Glucose in dH2O 
1.54 M KCl (74.6 g/mol) (Sigma # P-4504): 
  For 500 mL 
   57.4 g in dH2O 
1.30 M CaCl2 + 2 H2O (147.0 g/mol) (Sigma # C-3881): 
  For 250 mL 
   47.8 g in dH2O 
1.56 M MgSO4 + 7 H2O (246.5 g/mol) (Sigma # M-1880): 
  For 250 mL 
   96.1 g in dH2O 
0.13 M Na2 EDTA + 2 H2O (372.2 g/mol) (Sigma # E-5134): 
  For 500 mL 
   24.2 g in dH2O 
*store all above solutions @ 4°C 
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25 U/mL Insulin (27 U/mg) (Sigma # I-5500): 
  For 50 mL 
   46.3 mg in 0.01 M HCl 
*store @ -20°C 
NaHCO3 (84.0 g/mol) (Sigma # S-8875): 
 *Prepare Fresh Daily in dH2O 
 
Final Concentrations 
118.5 mM NaCl 
10 mM  Glucose 
4.7 mM KCl 
1.75 mM CaCl2 
1.2 mM MgSO4 
0.5 mM Na2 EDTA 
12 mU/mL Insulin 




Final Volume (L) 1.30  1.95  3.25  4.55  5.85 
NaCl + Glucose 40  60  100  140  180 
KCl   4  6  10  14  18 
CaCl2   1.75  2.62  4.37  6.13  7.88 
MgSO4  1  1.5  2.5  3.5  4.5 
Na2 EDTA  5  7.5  12.5  17.5  22.5 
 (All volumes in mL) 
* Combine all of the solutions listed above, filter into flask, and follow with 
1000 mL of dH2O. For volumes listed below greater than initial 1000 mL, add 
additional volume of dH2O to reservoir without filtering. Transfer filtered 
solution to reservoir and gas with 95:5 % O2/CO2 prior to adding NaHCO3 
solution. 
dH2O (mL)  1000  1500  2500  3500  4500 
* Dissolve solid NaHCO3 in 150 mL dH2O, filter into flask, and follow with 
remaining volume of dH2O. 
NaHCO3 (g)  2.70  4.05  6.75  9.45  12.15 
dH2O (mL)  247  371  617  863  1110 
* After all solutions have been gassed, add appropriate volume of insulin 
without filtering. 
25 U/mL Insulin (mL) 0.625  0.938  1.563  2.188  2.813 
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APPENDIX C- LDH ASSAY 
Solutions: 
Reaction buffer: 
For 20 mL 
Triethanolamine 0.473 M, pH 7.6 5.3 mL 
NADH   30 mM   150 µL 
Na2EDTA  130 mM  240 µL 
Pyruvate  1.0 M   50 µL 
in dH2O 
Procedure: 
1. Collect samples of coronary flow during perfusion, and store in 4°C until 
analysis. 
2. Add 250 µL of coronary effluent to 750 µL of reaction buffer in a 1.5 mL plastic 
cuvette. 
3. Record ∆ Abs @340 nm, between minutes 1 and 4 at 25°C. 
4. LDH (mU/min/g) = ∆ Abs x coronary flow rate (mL/min/g wet weight) x 788 
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APPENDIX D- HOMOGENIZATION PROTOCOL 
Solutions: 
Buffer: 
50 mM K2HPO4, 0.1 mM EDTA, 0.1% TRITON X-100, pH 7.4 
Procedure: 
1. Trim approximately 150 mg of left ventricle from frozen heart. 
2. Weigh tissue. 
3. Calculate buffer volume as: mass of tissue in grams X 19 = volume in mL of 
sodium phosphate buffer. 
4. Cut tissue into small pieces and place in homogenization tube. 
5. Add volume of buffer from step 3 to homogenization tube, and place on ice. 
6. Insert Teflon wand and start rotation of wand. 
7. Homogenize by making approximately 50 passes of the wand into the tube. 
8. Remove wand and inspect for non-homogenized pieces of tissue. Repeat 
additional passes if necessary. 
9. Strain homogenate through one layer of cheese cloth. 
10. Remove number of aliquots necessary for completion of assays and place 
remaining homogenate in -80°C. 
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APPENDIX E- LOWRY’S METHOD FOR DETERMINING PROTEIN CONCENTRATION 
Solutions: 
Protein Standard: 
 For 10 mL of 1 mg/mL stock: 
10 mg Bovine Serum Albumin (Sigma # A-4378) in dH2O. 
Solution A: 
 For 2000 mL 
40 g Na2CO3, 8 g NaOH, and 0.4 g NaK tartrate in dH2O. 
(Store in dark) 
Solution B: 
 For 1000 mL 
5 g CuSO4, 5H2O in dH2O. (Store in the dark) 
Solution C: 
50 parts Solution A to 1 part Solution B. (must be prepared fresh) 
Folin Ciocalteau’s Phenol Reagent (Sigma # F-9252): 




1. Standard Curve 
Prepare duplicate samples in the following manner: 






0.00 0 500 500 
0.03 15 485 500 
0.06 30 470 500 
0.09 45 455 500 
0.12 60 440 500 
0.15 75 425 500 
0.18 90 410 500 
0.21 105 395 500 
* note concentrations at 0.18 and 0.21 mg/mL are probably out of range, make 
sure std curve does not begin to level off if using these concentrations. 
2. Experimental Samples, Each sample is done in duplicate. Add 490 µL of dH2O, 
10 µL of sample, and 2.5 mL of Solution C. 
3. Initiation of reaction and reading, add 0.5 mL of diluted Folin Ciocalteau’s 
Phenol Reagent to each sample and vortex. Incubate at room temperature for 30 




APPENDIX F- AFFINITY CHROMATOGRAPHY PROTOCOL 
Solutions: 
Buffer: 
50 mM K2HPO4, 0.1 mM EDTA, 0.1% TRITON X-100, pH 7.4. 
Sepharose: 
2’5’ ADP Sepharose (Amersham # 17070001). 
10X PBS (phosphate buffered saline): 
For 1000 mL 
80 g NaCl, 2 g KCl, 14 g Na2HPO4 + 7 H2O, 2.4 g KH2PO4, pH 
7.4, in dH2O. 
1X PBS: 
 For 1000 mL 
100 mL of 10X PBS, in dH2O. 
Procedure: 
1. Place entire contents of sepharose bottle (5 g) into a 50 mL centrifuge tube, and 
wash three times with buffer according to manufacturer’s instructions. 
2. Measure volume of washed beads, and add an equivalent volume of buffer to 
make a 50% sepharose slurry. 
3. Spin 1 mL of the 1:20 tissue homogenate at 9,000 x g, for 10 minutes. Aspirate 
850 µL supernatant and retain. 




5. Spin samples at 5,000 x g for 5 minutes Aspirate 800 µL and retain pellet. 
6. Wash pellet 1 time x 5 minutes with 800 µL 1X PBS at 5,000 x g. 
7. Resuspend pellet in 50 µL of 2X sample buffer, boil for 5 minutes, and 
centrifuge at 8,000 x g for 5 minutes. 
8. Load 20 µL of supernatant onto gel, blot as described in western blotting 
optimization, Appendix I. 
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APPENDIX G- LAEMMLI SDS-PAGE (SODIUM DODECYL SULFATE – 
POLYACRYLAMIDE GEL ELECTROPHORESIS) PROCEDURE 
Solutions: 
40% acrylamide: 
Stock solution (Bio-Rad # 161-0140) 
2% bis-acrylamide: 
Stock solution (Bio-Rad # 161-0142) 
1.5 M Trizma: 
 For 500 mL 
90.83 g Trizma Base in dH2O, pH 6.8. 
1.25 M Trizma: 
 For 500 mL 
75.63 g Trizma Base in dH2O, pH 6.8. 
20% sodium dodecyl sulfate (20% SDS): 
Stock solution (Bio-Rad # 161-0418) 
TEMED: 
Stock Solution of N, N, N’, N’ - tetramethylethylenediamine 
(Sigma # 87689) 
ammonium persulfate (APS): 
 For 1 mL of 10% 
100 mg APS in dH2O. Prepared fresh daily. 
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10X Running Buffer: 
 For 1000 mL 
30.28 g Trizma 
144.2 g glycine 
in dH2O 
1X Running Buffer: 
For 1000 mL 
100 mL 10X Running Buffer 
5 mL 20 % SDS 
in dH2O 
dithiothreitol (DTT): 
 For 10 mL of 2 M 
3.086 g in dH2O. 
2X Sample Buffer: 
 2X Final 1X 
Concentration 
 
1.25 M Trizma, pH 6.8 5.0 mL 62.5 mM 
Glycerol 10.0 mL 10.0% 
20% SDS 5.0 mL 1.0% 
bromophenol blue 0.004 g 0.004% 
dH2O 25.0 mL  
To use sample buffer, add 100 µL of 2 M DTT to 0.9 mL of 2X sample buffer. 
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Resolving Gel 12.5%: 
 For every 
2 gels 
40% acrylamide 3.15 mL 
2% bis-acrylamide 0.35 mL 
1.5 M Trizma 2.5 mL 
20% SDS 50 µL 
dH2O 3.95 mL 
10% APS 32.5 µL 
TEMED 6.25 µL 
Add 10% APS and TEMED added prior to casting (Begins polymerization). 
Stacking Gel 5%: 
 For every 
2 gels 
40% acrylamide 1.25 mL 
2% bis-acrylamide 0.65 mL 
1.25 M Trizma 1 mL 
20% SDS 50 µL 
dH2O 6.99 mL 
10% APS 50 µL 
TEMED 10 µL 
Add 10% APS and TEMED added prior to casting (Begins polymerization). 
Procedure: 
1. Assemble gel apparatus according to manufacturer’s instructions in casting 
stand. 
Prepare resolving gel solution for number of gels to be cast. 
2. Gently swirl solution and then use a Pasteur pipette to fill caster 3/4 full. 
Overlay resolving gel with 200 µL of butanol and allow 1 hour for gel to 
polymerize. 
3. Pour butanol off the resolving gel and rinse with dH2O. 
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4. Prepare stacking gel solution for the number of gels cast, gently swirl solution, 
pour on top of the resolving gel and insert Teflon comb while avoiding bubbles. 
Allow 1 hour for polymerization. 
5. While the stacking gel is polymerizing prepare samples. Samples that were 
homogenized 1:20 in sodium phosphate buffer are further diluted 1:2 with 2X 
sample buffer (100 µL sample: 100 µL 2X sample buffer) and allow to incubate 
20 minutes at room temperature. Samples that were prepared through affinity 
chromatography will have been prepared in 1X sample buffer. Place samples in 
boiling water for 3 minutes prior to loading. 
6. Following polymerization of the stacking gel, assemble the gel apparatus for 
electrophoresis and place in the electrophoresis chamber. Fill the inner chamber 
with running buffer and bring the outer chamber to 1/4 full with running buffer. 
7. Load tissue homogenates (approximately 30 µL for homogenized samples and 
20 µL for affinity chromatography) and appropriate amounts of standard. 
Electrophorese at a constant 50 mA per 2 gels and a maximum of 200 V and 200 
W until the tracking dye runs off the gel. 
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APPENDIX H- WESTERN BLOTTING – SEMI-DRY TRANSFER 
Solutions: 
1 M Trizma: 
 For 1000 mL 
121.1 g Trizma 
in dH2O 
Anode 1 (for 1000 mL): 
Reagent Amount 
300 mM Trizma 300 mL of 1 M Trizma 
0.05% SDS 2.5 mL of 20% SDS 
10% Methanol 100 mL 
10 mM β-mercaptoethanol 0.78 mL 
Add reagents to ~500 mL dH2O and bring to volume. 
Anode 2 (for 1000 mL): 
Reagent Amount 
25 mM Trizma 25 mL of 1 M Trizma 
0.05% SDS 2.5 mL of 20% SDS 
10% Methanol 100 mL 
10 mM β-mercaptoethanol 0.78 mL 
Add reagents to ~500 mL dH2O and bring to volume. 
Cathode (for 1000 mL): 
Reagent Amount 
25 mM Trizma 25 mL of 1 M Trizma 
40 mM α-amino-hexanoic acid 5.248 g 
0.05% SDS 2.5 mL of 20% SDS 
10% Methanol 100 mL 
10 mM β-mercaptoethanol 0.78 mL 




1. During the SDS-PAGE procedure, pre-wet the PVDF membranes in 100% 
methanol and then soak in anode 1 for a minimum of 20 minutes. (Use one 
PVDF membrane per gel, cut to the same dimensions as gel 5x10 cm for Bio-
Rad mini-gel). 
2. Once SDS-PAGE is completed, remove the resolving gel and soak in anode 1 
for a minimum of 5 minutes. 
3. Wet two sheets of filter paper in anode 2. Place the 2 sheets of filter paper on the 
Bio-Rad Trans-Blot electrode. Roll a test tube over the top of each piece to 
remove air bubbles. 
4. Remove the PVDF membrane form anode 1 and place on top of the filter paper, 
remove air bubbles with test tube. 
5. Remove the gel from anode 1, place on top of the PVDF membrane, and remove 
air bubbles with gloved finger. 
6. Wet two sheets of filter paper in cathode, stack the sheets on top of the gel, and 
remove air bubbles with test tube. 
7. Transfer the proteins from the gel to the PVDF membrane at a constant 150 mA, 
15 V, and a maximum of 200 W for 35 minutes. 
8. Following the transfer, place the PVDF membrane in dH2O and refrigerate until 
immunoblotting is performed. 
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APPENDIX I- WESTERN BLOTTING - IMMUNOBLOTTING 
Solutions: 
10X PBS (phosphate buffered saline): 
 For 1000 mL 
80 g NaCl 
2 g KCL 
14 g Na2HPO4 + 7 H2O 
2.4 g KH2PO4 
pH 7.4 in dH2O 
1X PBS-.1% Tween: 
 For 1000 mL 
100 mL 10X PBS 
1 mL of Tween 20 
in dH2O 
Primary antibody: 
Dilute primary antibody to optimal concentration (Appendix J) in 
1XPBS-Tween (10 mL per gel) with 1% milk. 
Secondary antibody: 
Dilute appropriate HRP-labeled secondary antibody to optimized 




1. Block PVDF membranes for 1 hour at room temperature or overnight at 4°C in 
1X PBS with 5% milk. 
2. Rinse the membranes with two quick washes of 1XPBS-Tween. 
3. Incubate membranes with primary antibody for 1 hour at room temperature on 
orbital shaker. 
4. Wash 3X10 minutes in 1XPBS-Tween. 
5. Incubate 1 hour with secondary antibody. 
6. Wash 5X5 minutes with 1XPBS-Tween. 
7. Rinse 3 times with dH2O. 
8. Prepare the membranes for autoradiography using PIERCE SuperSignal 
solutions (Pierce Chemical, Rockford, IL) according to manufacturer’s 
instructions. 
9. Expose membranes to Kodak Biomax film (no. Z370398, Sigma Aldrich Inc., St 
Louis, MO) for previously determined optimal exposure time. 
10. Develop film according to manufacturer’s instructions (Kodak autoradiography 
processing chemicals, no. p7042 & p7167, Sigma Aldrich Inc., St Louis, MO). 
11. Images are then scanned into an Apple Power PC computer, and the density of 




APPENDIX J- BLOTTING OPTIMIZATION  
HSP70: 
Primary antibody 
HSP70 (W27) mouse monoclonal IgG (no. sc-24, Santa Cruz Biotechnology) 
diluted 1:200. 
Secondary antibody 
Anti-mouse IgG HRP (horseradish peroxidase-linked whole antibody from 
sheep; no. NXA 931, Amersham Life Sciences) diluted 1:2500. 
UCP2: 
Primary antibody 
UCP2 (C-20) goat polyclonal IgG (no. sc-6525, Santa Cruz Biotechnology) 
diluted 1:100. 
Secondary antibody 
Anti-goat IgG HRP (horseradish peroxidase-linked whole antibody from rabbit; 
no. sc-2768, Santa Cruz Biotechnology) diluted 1:20,000. 
eNOS: 
Primary antibody 
eNOS mAb (no. 610297, BD Biosciences, San Diego, CA) diluted 1:200. 
Secondary antibody 
Anti-mouse IgG HRP (horseradish peroxidase-linked whole antibody from 





iNOS mAb (no. 610329, BD Biosciences, San Diego, CA) diluted 1:100. 
Secondary antibody 
Anti-mouse IgG HRP (horseradish peroxidase-linked whole antibody from 
sheep; no. NXA 931, Amersham Life Sciences) diluted 1:2000. 
nNOS: 
Primary antibody 
nNOS mAb (no. 610309, BD Biosciences, San Diego, CA) diluted 1:100. 
Secondary antibody 
Anti-mouse IgG HRP (horseradish peroxidase-linked whole antibody from 
sheep; no. NXA 931, Amersham Life Sciences) diluted 1:2000. 
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APPENDIX K- CATALASE ASSAY 
Sample Preparation: 
1. Pipette 1 mL of tissue homogenate into centrifuge tube. 
2. Centrifuge 1,500 x g for 10 minutes at 4°C, retain supernatant for analysis. 
Solutions: 
Buffer: 
50 mM K2HPO4, 0.1 mM EDTA, 0.1% TRITON X-100, pH 7.4. 
Hydrogen Peroxide: 
1 M H2O2 stock solution 
Procedure: 
1. Equilibrate the incubation buffer with N2 gas in order to decrease O2 
concentration to a very low amount so that the O2 produced from the catalase 
reaction will remain in solution during the assay. 
2. Add 1.5 mL nitrogen-equilibrated buffer to the oxygen electrode cuvette. 
3. Add 15 µL of supernatant and obtain baseline oxygen production rate. 
4. Add 15 µL of 1 M H2O2 to initiate the reaction and obtain oxygen production 
rate. (Final concentration of H2O2 = 9.8 mM). 
Calculations: 
Catalase activity in Units/mg heart wet weight.  
Where 1 Unit = 1 µmol H2O2/min 
Net O2 production rate (Step 4 - Step 3) X 2 (as 2 hydrogen peroxides are 
consumed for each oxygen produced) divided by amount of tissue in 15 µL. 
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APPENDIX L- SUPEROXIDE DISMUTASE ASSAY 
Sample Preparation: 
1. Pipette 1 mL of tissue homogenate into centrifuge tube. 
2. Centrifuge 1,500 x g for 10 minutes at 4°C. 
3. Retain supernatant for analysis. 
Solutions: 
Solution A: 
50 mM KH2PO4, 0.1 mM EDTA, 0.05 mM xanthine, 0.01 mM 
cyrochrome c, in dH2O. 
Potassium Cyanide (KCN): 
2 mM in dH2O. 
Xanthine Oxidase (XO): 
1:40 v:v in dH2O. 
Procedure: 
1. Set up spectrophotometer to read the reaction for 3 minutes at a wavelength of 
550 nm. 
2. Determine baseline without supernatant. Baseline is the rate of superoxide/cyto 
c, reaction without SOD. To a 3 mL cuvette, add 1.4 mL of solution A. Place the 
cuvette in the spectrophotometer and start reaction with 10 µL of XO. Record 
the absorbance at 30 and 150 seconds after adding XO. Absorbance at 150 
seconds – absorbance at 30 seconds = baseline absorbance change. 
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3. Determine rate with supernatant (containing MnSOD). To a cuvette, add 1.3 mL 
of solution A, 10 µL of supernatant, and 10 µL of KCN, which inhibits 
CuZnSOD (final concentration of KCN = 2.0 mM). Place the cuvette in the 
spectrophotometer and start reaction with 10 µL XO as in Step 2 and record 
absorbance at 30 and 150 seconds after adding xanthine oxidase. Absorbance at 
150 seconds – absorbance at 30 seconds = sample absorbance change. 
Calculations: 
Percent inhibition of baseline = (baseline absorbance change – sample 
absorbance change)/baseline absorbance change. 
Units MnSOD/mg heart wet weight = percent inhibition of baseline X 0.02 
divided by mg heart tissue in cuvette. One unit = 50% inhibition of baseline. 
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APPENDIX M- RAW DATA 
CF (mL/min/g heart wet weight)     
sedentary (SED)          
D pre 5 10 15 20 25 30 
119 11.8 13.6 15.3 14.1 11 10.8 11.1 
120 14.3 14.3 15 14.1 11.8 11.8 12 
124 12.8 15.6 15.3 11.6 11.4 11.7 11.9 
125 14.7 13.1 13.7 13.3 11.3 11.8 12.2 
126 12.4 14.5 14 14.2 10.8 10.6 10.2 
127 12.9 13 13.7 9.6 9.5 9.6 9.6 
131 15.6 14.1 14.6 16.8 16.6 14.4 15.2 
mean 13.5 14.029 14.514 13.386 11.771 11.529 11.743 
SD 1.3808 0.9013 0.7151 2.2682 2.25 1.5019 1.8091 
n 7 7 7 7 7 7 7 
SE 0.5219 0.3407 0.2703 0.8573 0.8504 0.5677 0.6838 
2 days run (RUN)      
D pre 5 10 15 20 25 30 
117 13.5 14.4 13.8 12.7 12.8 12.9 13.4 
118 12.6 14.2 14.9 11.4 11.8 11.9 11.9 
121 15.7 16.7 17 16.1 15.9 15.8 14.9 
123 16.9 17.4 17.7 17.9 18.6 18.6 18.5 
128 12.8 14.5 16 13.2 13.3 12.8 13.2 
129 14.2 17.4 18.1 15.2 14.8 14.7 14.5 
130 13.4 14.3 16.3 13.7 13.6 13.4 13.2 
mean 14.157 15.557 16.257 14.314 14.4 14.3 14.229 
SD 1.5904 1.5263 1.5263 2.2192 2.2811 2.2978 2.1211 
n 7 7 7 7 7 7 7 




sedentary/MPG (SED/MPG)     
D pre 5 10 15 20 25 30 
133 18.8 16 16.8 19.7 19.7 19.9 21.4 
134 13.1 14.5 15 12.4 10.7 10.7 11.1 
135 13 17.7 16.8 13 12.6 12.4 12.4 
136 13.1 16.1 13.5 11.3 11.3 11.3 11.3 
137 16.4 21.4 15.9 14.9 15 14.6 15 
138 14.4 17.5 16.1 12.4 11.8 11.3 11.7 
145 14.8 15.8 16.2 14.6 14 14 14.4 
147 15.7 15.5 15.1 13.6 13.7 13.9 14.7 
182 21.2 17.6 17.1 21.3 21.8 21.4 21.9 
183 14.9 16.3 16.6 13.5 13.4 13.2 13.5 
194 15 15.3 16.4 13.1 13.2 13.6 13.2 
195 14.9 12.1 13.1 12.6 11.3 11.6 12 
mean 15.442 16.317 15.717 14.367 14.042 13.992 14.383 
SD 2.4239 2.2156 1.2995 3.044 3.4068 3.3646 3.6369 
n 12 12 12 12 12 12 12 
SE 0.6997 0.6396 0.3751 0.8787 0.9835 0.9713 1.0499 
2 days run/MPG (RUN/MPG)     
D pre 5 10 15 20 25 30 
139 14.1 14.6 14.6 13.7 13.7 13.7 14.4 
141 12.8 19.5 19.5 13.2 13.5 14.3 14 
142 10.2 22 23.3 15.2 11.8 12.3 12.5 
143 13.2 16.3 15.3 13.3 13.7 13.6 13.7 
146 14.3 16.7 15.3 14.7 11.9 11.7 12 
151 13.7 19.8 18.6 15.8 15.8 15.5 15.4 
152 16.2 18.6 19.6 18.3 17.6 17.7 17.4 
153 13 19.1 17.5 13.8 13.9 13.1 13.2 
197 12.8 20.3 17.2 13.4 13.5 12.8 12.8 
198 14.7 20.9 19.5 14.5 13.7 14 13.7 
mean 13.5 18.78 18.04 14.59 13.91 13.87 13.91 
SD 1.5628 2.2807 2.6357 1.5652 1.7045 1.7173 1.5673 
n 10 10 10 10 10 10 10 





sedentary, L-NAME perfused (SED/L-N)    
D pre 5 10 15 20 25 30 
157 12.2 13.6 12.2 10.4 9.8 9.9 9.7 
158 11.8 12.9 11.6 10.1 10 8.2 8.4 
159 10.6 13.4 10.7 9.2 8.3 8 6.9 
160 11.8 16.3 11.2 10.8 10.5 10.4 8.8 
171 10.7 11.5 13.5 8.6 8.4 8.7 9.2 
172 8.5 16 12.6 9.5 9.1 9.2 9.2 
mean 10.933 13.95 11.967 9.7667 9.35 9.0667 8.7 
SD 1.356 1.8577 1.0132 0.8165 0.8961 0.9501 0.9839 
n 6 6 6 6 6 6 6 
SE 0.5536 0.7584 0.4137 0.3333 0.3658 0.3879 0.4017 
2 days run, L-NAME perfused (RUN/L-N)       
D pre 5 10 15 20 25 30 
161 10.9 16.8 12.3 10.7 10.8 10.7 10.6 
162 11.7 15.5 13.2 11 11.3 10.2 11.2 
163 10.9 14.4 14.2 10 10.3 10.1 10.6 
165 13.5 16.6 14.6 13.4 13.7 14.1 14.3 
166 12.8 15.8 13.6 11.4 11.2 11.3 10.9 
168 11.3 16.2 12.5 11 11.1 10.7 10.6 
mean 11.85 15.883 13.4 11.25 11.4 11.183 11.367 
SD 1.0728 0.8727 0.9143 1.152 1.1832 1.4919 1.4569 
n 6 6 6 6 6 6 6 
SE 0.438 0.3563 0.3733 0.4703 0.483 0.6091 0.5948 
2 days run/Cold, L-NAME perfused (CRUN/L-N)   
D pre 5 10 15 20 25 30 
173 12.9 15 14.1 12.9 13.4 12.6 13.1 
175 13.6 11.6 15.1 11.7 11.9 11.4 11.5 
176 13 15.7 15.9 11.8 11.9 11.7 12 
177 12.4 16 13 12.1 12.9 12.4 12.4 
178 12.3 14.5 12.9 11.7 11.6 11.6 11.9 
180 11.7 17 10.5 10.9 10.8 10.5 10.3 
181 10.8 16.4 12.2 10.6 10.5 10.8 10.7 
mean 12.386 15.171 13.386 11.671 11.857 11.571 11.7 
SD 0.9227 1.7821 1.8206 0.7588 1.0406 0.7675 0.9644 
n 7 7 7 7 7 7 7 
SE 0.3488 0.6736 0.6881 0.2868 0.3933 0.2901 0.3645 
 
108
LDH (mU/min/g heart wet weight)        
sedentary (SED)          
D pre 5 10 15 20 25 30 
119 8.3686 120.03 278.5 166.66 57.209  48.107 
120 16.903 175.79 218.67 185.55 52.071  53.899 
124 43.372 302.4 213.4 118.83 100.61  75.018 
125 49.809 507.88 562.45 504.11 322.34  201.89 
126 33.222 284.51 788.79 671.38 211.06  211.39 
127 44.727 582.88 528.98 239.8 151.22  96.073 
131 34.42 127.77 391.16 487.17 421.2  197.63 
mean 32.974 300.18 425.99 339.07 187.96  126.29 
SD 15.251 183.01 212.91 212.62 139.96  74.095 
n 7 7 7 7 7  7 
SE 5.7643 69.173 80.474 80.364 52.9  28.005 
2 days run (RUN)      
D pre 5 10 15 20 25 30 
117 9.5742 138.44 192.48 97.074 83.717  68.635 
118 45.672 245.05 146.77 103.31 56.72  50.637 
121 30.929 223.71 150.04 105.3 58.887  12.915 
123 67.918 263.26 140.87 122.72 90.872  90.384 
128 15.13 281.08 260.99 164.35 92.228  82.173 
129 31.331 283.82 193.97 113.79 54.813  49.132 
130 28.51 296.36 348.08 218.07 136.1  130.02 
mean 32.723 247.39 204.74 132.09 81.906  69.128 
SD 19.471 54.082 75.73 44.023 28.942  37.04 
n 7 7 7 7 7  7 





sedentary/MPG (SED/MPG)         
D pre 5 10 15 20 25 30 
133 14.814 165.16 158.86 104.01 66.751  69.139 
134 19.613 270.8 301.41 334.18 123.94  181.06 
135 38.927 198.06 139 107.56 98.295  53.742 
136 38.194 238.51 261.69 162.95 62.331  56.098 
137 42.647 150.08 144.09 79.84 20.094  22.458 
138 46.524 206.85 107.84 128 55.79  49.786 
145 18.66 263.95 209.36 369.3 292.35  312.05 
147 21.032 431.15 403.37 445.82 619.67  371.83 
182 23.388 198.32 167.09 105.74 54.971  20.709 
183 29.353 120.74 290.39 214.89 162.61  131.91 
194 28.368 429.21 638.41 338.59 173.71  85.293 
195 34.049 387.11 643.11 607.64 216.38  242.07 
mean 29.631 255 288.72 249.88 162.24  133.01 
SD 10.396 106.73 184.86 168 164.3  118.17 
n 12 12 12 12 12  12 
SE 3.0011 30.811 53.366 48.499 47.429  34.113 
2 days run/MPG (RUN/MPG)         
D pre 5 10 15 20 25 30 
139 18.888 144.96 161.07 133.87 109.04  41.985 
141 20.173 161.34 142.9 88.414 46.807  23.167 
142 21.702 173.36 220.32 318.6 91.124  74.86 
143 9.3614 136.15 136.24 55.546 32.387  15.114 
146 13.522 228.98 364.1 257.16 155.66  93.614 
151 11.875 43.687 33.711 29.881 14.94  14.562 
152 15.319 124.58 86.491 79.312 49.928  26.051 
153 18.439 94.82 91.014 54.372 43.813  31.205 
197 31.268 60.786 29.818 36.957 28.723  19.164 
198 39.384 67.524 53.781 49.132 26.989  28.069 
mean 19.993 123.62 131.95 110.32 59.941  36.779 
SD 9.1432 57.662 101.45 99.256 44.625  26.642 
n 10 10 10 10 10  10 





sedentary, L-NAME perfused (SED/L-N)    
D pre 5 10 15 20 25 30 
157 12.498 161.82 177.85 99.981 40.929  47.39 
158 13.948 240.92 301.65 225.23 151.3  92.007 
159 20.882 336.84 349.91 314.63 202.1  197.37 
160 11.158 147.71 103.26 60.424 55.436  40.913 
171 14.334 63.434 179.78 115.21 84.726  55.097 
172 12.726 172.73 122.12 67.374 32.986  28.273 
mean 14.258 187.24 205.76 147.14 94.578  76.842 
SD 3.4361 92.745 98.923 101.27 67.939  62.844 
n 6 6 6 6 6  6 
SE 1.4028 37.863 40.385 41.343 27.736  25.656 
2 days run, L-NAME perfused (RUN/L-N)       
D pre 5 10 15 20 25 30 
161 13.743 128.41 92.078 42.158 23.829  17.541 
162 12.907 119.7 81.132 52.875 29.385  37.95 
163 11.166 124.82 193.58 155.24 80.352  76.846 
165 13.829 117.73 70.179 40.125 35.625  12.395 
166 17.147 98.358 84.663 38.628 17.651  11.166 
168 32.946 114.89 61.07 39.006 24.491  23.388 
mean 16.956 117.32 97.117 61.338 35.222  29.881 
SD 8.0715 10.493 48.51 46.305 22.911  24.985 
n 6 6 6 6 6  6 
SE 3.2952 4.2839 19.804 18.904 9.3536  10.2 
2 days run/Cold, L-NAME perfused (CRUN/L-N)   
D pre 5 10 15 20 25 30 
173 31.512 213.94 171.11 110.8 62.299  64.001 
175 24.649 48.446 253.44 325.45 223.18  259.17 
176 45.074 176.91 146.59 108.79 55.325  61.464 
177 36.153 105.91 91.172 57.209 57.942  53.742 
178 55.247 85.695 55.909 54.396 39.305  42.197 
180 23.049 151.37 62.882 59.265 33.191  38.147 
181 25.531 125.36 38.454 37.588 17.375  29.511 
mean 34.459 129.66 117.08 107.64 69.802  78.319 
SD 11.99 56.153 77.371 100.07 69.462  80.728 
n 7 7 7 7 7  7 
SE 4.5316 21.224 29.243 37.821 26.254  30.512 
 
111
AF (mL/min/g heart wet weight)   
sedentary (SED)        
D pre 15 20 25 30
119 38.9 0 10.6 12.9 18.4
120 40 0 14.2 19.4 20.2
124 45.1 29.9 34.8 31.6 33.7
125 51.1 0 10.3 10.7 11.3
126 28.9 0 8.6 10 11.7
127 40.7 24.3 24.2 23.8 21.3
131 44.7 0 0 15.9 17.7
mean 41.343 7.7429 14.671 17.757 19.186
SD 6.875 13.322 11.431 7.83 7.4968
n 7 7 7 7 7
SE 2.5985 5.0352 4.3204 2.9595 2.8335
2 days run (RUN)    
D pre 15 20 25 30
117 45.8 23.4 25.9 26.2 26.2
118 37.8 13.9 21 22.8 24.2
121 45.8 33.1 34.4 37.3 36.1
123 53.8 43.4 42 44 43.9
128 42.5 24.2 32.1 32.7 33.1
129 48.3 37.6 38.9 41.1 39.6
130 45.5 27.2 30 31.2 30.9
mean 45.643 28.971 32.043 33.614 33.429
SD 4.9169 9.8639 7.2523 7.7036 7.0568
n 7 7 7 7 7





sedentary/MPG (SED/MPG)   
D pre 15 20 25 30
133 42.4 16.5 17.5 17.9 25
134 39.9 0 11 13 14.2
135 42.7 34.2 35.9 37.1 38
136 40.6 27.1 29.4 29.7 29.7
137 55.7 41.3 44 44.5 46.8
138 44.5 21.7 22.5 22.5 28.9
145 52.3 0 0 0 0
147 46.9 0 0 0 0
182 51.3 33.7 34.3 34.9 34.3
183 52 22.8 25.2 26.3 26.1
194 54 24.9 26.6 27.1 27.4
195 53.3 0 12 12.9 13.4
mean 47.967 18.517 21.533 22.158 23.65
SD 5.7369 15.118 13.888 13.99 14.316
n 12 12 12 12 12
SE 1.6561 4.3641 4.009 4.0387 4.1326
2 days run/MPG (RUN/MPG)   
D pre 15 20 25 30
139 43.5 27.5 29.9 30.3 30.9
141 41.8 23.7 26.1 26.9 27.2
142 35.2 0 6.2 9.3 21.9
143 39.7 29.7 31.8 32.1 32.4
146 45.1 0 12.9 15.7 17.3
151 44.1 39.1 39.7 38.5 36.7
152 42.7 33 34.8 35.8 36.1
153 40.6 31.5 31.8 31.7 30.7
197 44.7 40.2 38.8 38.6 39.1
198 49.7 44.9 45.1 44.2 42.6
mean 42.71 26.96 29.71 30.31 31.49
SD 3.8272 15.541 12.029 10.701 7.7694
n 10 10 10 10 10





sedentary, L-NAME perfused (SED/L-N)  
D pre 15 20 25 30
157 42.6 20.6 20.8 22.3 23.7
158 47.3 0 0 5.4 7
159 39.4 0 0 0 3.2
160 50.9 38.8 38.3 36.8 21.2
171 46.4 16.7 18.5 27.2 27.1
172 38.1 28.9 30.3 31.7 32.3
mean 44.117 17.5 17.983 20.567 19.083
SD 4.9418 15.533 15.617 14.748 11.515
n 6 6 6 6 6
SE 2.0175 6.3414 6.3757 6.0208 4.7012
2 days run, L-NAME perfused (RUN/L-N)     
D pre 15 20 25 30
161 47.7 37.3 37.5 37.7 38.6
162 53.9 40.2 36.3 22.4 39.9
163 45.6 21 27.3 29.3 29.6
165 51.2 41 42.6 43.2 42.3
166 49 37.4 39 36.9 37
168 47.6 37.7 38.5 38.5 38.6
mean 49.167 35.767 36.867 34.667 37.667
SD 2.9629 7.4007 5.1446 7.4963 4.3293
n 6 6 6 6 6
SE 1.2096 3.0213 2.1003 3.0604 1.7674
2 days run/Cold, L-NAME perfused (CRUN/L-N) 
D pre 15 20 25 30
173 45.1 33.2 35 32.4 32.1
175 48.9 16.9 29.1 30.7 31.6
176 49.2 34.1 37 36.8 37.8
177 49.8 40.4 41.7 41.3 41
178 46.6 38.6 38.8 39 37.8
180 41.3 30.1 40.1 40.8 41.2
181 44.1 40.3 41.1 40.1 40.8
mean 46.429 33.371 37.543 37.3 37.471
SD 3.1271 8.2393 4.3988 4.219 4.1023
n 7 7 7 7 7
SE 1.182 3.1142 1.6626 1.5946 1.5505
 
114
CO (mL/min/g heart wet weight)   
sedentary (SED)        
D pre 15 20 25 30
119 50.7 14.1 21.6 23.7 29.5
120 54.3 14.1 26 31.2 32.2
124 57.9 41.5 46.2 43.3 45.6
125 65.8 13.3 21.6 22.5 23.5
126 41.3 14.2 19.4 20.6 21.9
127 53.6 33.9 33.7 33.4 30.9
131 60.3 16.8 16.6 30.3 32.9
mean 54.843 21.129 26.443 29.286 30.929
SD 7.7631 11.583 10.3 7.8603 7.7405
n 7 7 7 7 7
SE 2.9342 4.3778 3.8932 2.9709 2.9256
2 days run (RUN)    
D pre 15 20 25 30
117 59.3 36.1 38.7 39.1 39.6
118 50.4 25.3 32.8 34.7 36.1
121 61.5 49.2 50.3 53.1 51
123 70.7 61.3 60.6 62.6 62.4
128 55.3 37.4 45.4 45.5 46.3
129 62.5 52.8 53.7 55.8 54.1
130 58.8 40.9 43.6 44.6 44.1
mean 59.786 43.286 46.443 47.914 47.657
SD 6.3094 12.01 9.3382 9.7798 8.9723
n 7 7 7 7 7





sedentary/MPG (SED/MPG)   
D pre 15 20 25 30
133 61.2 36.2 37.2 37.8 46.4
134 53 12.4 21.7 23.7 25.3
135 55.7 47.2 48.5 49.5 50.4
136 53.7 38.4 40.7 41 41
137 72.1 56.2 59 59.1 61.8
138 58.9 34.1 34.3 33.8 40.6
145 67.1 14.6 14 14 14.4
147 62.6 13.6 13.6 13.9 14.7
182 72.5 55 56.5 56.3 56.2
183 66.9 36.3 38.6 39.5 39.6
194 69 38 39.8 40.2 40.6
195 68.2 12.6 23.3 24.5 25.4
mean 63.408 32.883 35.6 36.108 38.033
SD 6.9158 16.112 15.084 14.914 15.276
n 12 12 12 12 12
SE 1.9964 4.6512 4.3543 4.3053 4.4098
2 days run/MPG (RUN/MPG)   
D pre 15 20 25 30
139 57.6 41.2 43.6 44 45.3
141 54.6 36.9 39.6 41.2 41.2
142 45.2 15.2 18 21.6 34.4
143 52.9 43 45.5 45.7 46.1
146 59.4 14.7 24.8 27.4 29.3
151 57.8 54.9 55.5 54 52.1
152 58.9 51.3 52.4 53.5 53.5
153 53.6 45.3 45.7 44.8 43.9
197 57.5 53.6 52.3 51.4 51.9
198 64.4 59.4 58.8 58.2 56.3
mean 56.19 41.55 43.62 44.18 45.4
SD 5.0792 15.6 13.16 11.714 8.642
n 10 10 10 10 10





sedentary, L-NAME perfused (SED/L-N)  
D pre 15 20 25 30
157 54.8 31 30.6 32.2 33.4
158 59.1 10.1 10 13.6 15.4
159 50 9.2 8.3 8 10.1
160 62.7 49.6 48.8 47.2 30
171 57.1 25.3 26.9 35.9 36.3
172 46.6 38.4 39.4 40.9 41.5
mean 55.05 27.267 27.333 29.633 27.783
SD 5.9346 15.885 16 15.534 12.355
n 6 6 6 6 6
SE 2.4228 6.4849 6.532 6.3415 5.0438
2 days run, L-NAME perfused (RUN/L-N)     
D pre 15 20 25 30
161 58.6 48 48.3 48.4 49.2
162 65.6 51.2 47.6 32.6 51.1
163 56.5 31 37.6 39.4 40.2
165 64.7 54.4 56.3 57.3 56.6
166 61.8 48.8 50.2 48.2 47.9
168 58.9 48.7 49.6 49.2 49.2
mean 61.017 47.017 48.267 45.85 49.033
SD 3.6307 8.1918 6.0708 8.6199 5.3084
n 6 6 6 6 6
SE 1.4822 3.3443 2.4784 3.5191 2.1671
2 days run/Cold, L-NAME perfused (CRUN/L-N) 
D pre 15 20 25 30
173 58 46.1 48.4 45 45.2
175 62.5 28.6 41 42.1 43.1
176 62.2 45.9 48.9 48.5 49.8
177 62.2 52.5 54.6 53.7 53.4
178 58.9 50.3 50.4 50.6 49.7
180 53 41 50.9 51.3 51.5
181 54.9 50.9 51.6 50.9 51.5
mean 58.814 45.043 49.4 48.871 49.171
SD 3.7927 8.2272 4.2218 4.0269 3.6976
n 7 7 7 7 7
SE 1.4335 3.1096 1.5957 1.522 1.3976
 
117
HR (beats/min)        
sedentary (SED)        
D pre 15 20 25 30
119 237 98 243 237 237
120 279 271 304 303 298
124 293 294 295 294 295
125 295   244 244
126 254 195 250 256 209
127 296 295 295 295 294
131 283 218 242 257 258
mean 276.71 228.5 271.5 269.43 262.14
SD 22.765 75.87 29.345 27.135 34.6
n 7 6 6 7 7
SE 8.6043 30.974 11.98 10.256 13.077
2 days run (RUN)    
D pre 15 20 25 30
117 302 299 297 288 293
118 329 299 307 313 319
121 294 294 294 293 294
123 293 293 291 293 293
128 294 304 294 294 295
129 294 296 295 295 294
130 294 295 295 296 295
mean 300 297.14 296.14 296 297.57
SD 13.153 3.8048 5.113 7.9162 9.4843
n 7 7 7 7 7





sedentary/MPG (SED/MPG)   
D pre 15 20 25 30
133 295 295 295  295
134 261  240 241 247
135 295 295 294 295 295
136 295 294 295 295 295
137 295 295 294 295 295
138 294 295 295 295 295
145 298 163 208 115 219
147 270 220 156 100 150
182 295 295 295 295 295
183 279 257 265 269 272
194 295 295 295 295 295
195 323  237 235 235
mean 291.25 270.4 264.08 248.18 265.67
SD 15.557 45.268 45.438 73.148 45.636
n 12 10 12 11 12
SE 4.4909 14.315 13.117 22.055 13.174
2 days run/MPG (RUN/MPG)   
D pre 15 20 25 30
139 295 295 295 295 295
141 269 230 237 240 246
142 254 103 174 170 285
143 295 295 295 295 295
146 281 229 248 250 253
151 295 295 295 295 295
152 295 295 295 295 295
153 295 295 295 295 295
197 295 295 295 295 295
198 295 295 295 295 295
mean 286.9 262.7 272.4 272.5 284.9
SD 14.518 62.372 40.969 41.65 18.988
n 10 10 10 10 10





sedentary, L-NAME perfused (SED/L-N)  
D pre 15 20 25 30
157 267 228 216 226 241
158 277 235 228 256 258
159 270 204 180 181 210
160 295 293 294 292 194
171 295 295 295 295 295
172 301 283 278 289 288
mean 284.17 256.33 248.5 256.5 247.67
SD 14.593 38.852 47.479 45.672 40.786
n 6 6 6 6 6
SE 5.9577 15.861 19.383 18.645 16.651
2 days run, L-NAME perfused (RUN/L-N)     
D pre 15 20 25 30
161 295 295 295 295 295
162 295 295 295 295 295
163 289 331 320 323 304
165 295 295 295 295 295
166 294 295 294 294 295
168 319 294 294 295 294
mean 297.83 300.83 298.83 299.5 296.33
SD 10.629 14.784 10.381 11.52 3.7771
n 6 6 6 6 6
SE 4.3391 6.0355 4.2381 4.7028 1.542
2 days run/Cold, L-NAME perfused (CRUN/L-N) 
D pre 15 20 25 30
173 295 295 295 295 295
175 294  293 293 293
176 295 295 295 295 295
177 295 295 295 295 295
178 295 295 295 295 295
180 295 295 295 295 295
181 295 295 295 295 295
mean 294.86 295 294.71 294.71 294.71
SD 0.378 0 0.7559 0.7559 0.7559
n 7 6 7 7 7
SE 0.1429 0 0.2857 0.2857 0.2857
 
120
SP (mmHg)     
sedentary (SED)        
D pre 15 20 25 30
119 126 111 97 99 107
120 119 111 107 111 114
124 113 102 103 101 102
125 108  98 93 95
126 111 106 90 90 101
127 110 95 95 95 95
131 112 92 106 92 95
mean 114.14 102.83 99.429 97.286 101.29
SD 6.2564 8.0353 6.1875 7.1813 7.2276
n 7 6 7 7 7
SE 2.3647 3.2804 2.3387 2.7143 2.7318
2 days run (RUN)    
D pre 15 20 25 30
117 106 104 107 110 111
118 113 99 103 106 109
121 113 105 107 107 109
123 107 104 103 106 107
128 116 120 109 113 115
129 113 107 108 109 110
130 109 100 101 103 103
mean 111 105.57 105.43 107.71 109.14
SD 3.6968 6.9488 3.0472 3.2514 3.671
n 7 7 7 7 7





sedentary/MPG (SED/MPG)   
D pre 15 20 25 30
133 108 98 94  99
134 121  97 98 99
135 102 94 95 97 97
136 106 91 91 91 91
137 112 110 111 111 111
138 108 92 93 93 95
145 110 85 87 97 97
147 113 86 88 90 97
182 112 103 103 104 104
183 111 104 105 106 106
194 122 96 97 98 100
195 105  96 96 99
mean 110.83 95.9 96.417 98.273 99.583
SD 5.9365 8.0201 6.9995 6.4201 5.2822
n 12 10 12 11 12
SE 1.7137 2.5362 2.0206 1.9357 1.5248
2 days run/MPG (RUN/MPG)   
D pre 15 20 25 30
139 109 96 100 101 101
141 106 107 107 109 108
142 113 106 101 105 94
143 102 99 100 101 100
146 115 96 98 100 101
151 112 105 106 106 106
152 108 102 102 103 104
153 102 95 96 97 96
197 114 111 112 114 114
198 107 103 103 103 104
mean 108.8 102 102.5 103.9 102.8
SD 4.6857 5.3955 4.7199 4.8865 5.808
n 10 10 10 10 10





sedentary, L-NAME perfused (SED/L-N)  
D pre 15 20 25 30
157 112 102 103 104 102
158 107 83 93 82 84
159 116 85 90 99 87
160 115 104 103 103 113
171 108 85 84 89 89
172 93 93 94 96 97
mean 108.5 92 94.5 95.5 95.333
SD 8.4083 9.2087 7.4498 8.5499 10.93
n 6 6 6 6 6
SE 3.4327 3.7594 3.0414 3.4905 4.4622
2 days run, L-NAME perfused (RUN/L-N)     
D pre 15 20 25 30
161 108 102 102 102 103
162 110 103 107 118 106
163 111 94 99 103 104
165 111 108 106 108 109
166 116 111 112 113 113
168 111 104 104 105 106
mean 111.17 103.67 105 108.17 106.83
SD 2.6394 5.8195 4.4721 6.2423 3.656
n 6 6 6 6 6
SE 1.0775 2.3758 1.8257 2.5484 1.4926
2 days run/Cold, L-NAME perfused (CRUN/L-N) 
D pre 15 20 25 30
173 122 116 116 118 119
175 120  114 118 120
176 110 107 107 106 108
177 114 111 111 112 114
178 110 106 106 110 110
180 114 104 105 109 113
181 111 107 108 110 112
mean 114.43 108.5 109.57 111.86 113.71
SD 4.8255 4.3243 4.1975 4.5617 4.424
n 7 6 7 7 7
SE 1.8239 1.7654 1.5865 1.7242 1.6721
 
123
COxSP (mmHgxmL/min/g heart wet weight)     
sedentary (SED)        
D pre 15 20 25 30
119 6388 1565 2095 2346 3157
120 6462 1565 2782 3463 3671
124 6543 4233 4759 4373 4651
125 7106  2117 2093 2233
126 4584 1505 1746 1854 2212
127 5896 3221 3202 3173 2936
131 6754 1546 1760 2788 3126
mean 6247.6 2272.5 2637.3 2870 3140.9
SD 820.31 1171.4 1077.8 877.47 845.68
n 7 6 7 7 7
SE 310.05 478.23 407.38 331.65 319.64
2 days run (RUN)    
D pre 15 20 25 30
117 6286 3754 4141 4301 4396
118 5695 2508 3378 3678 3935
121 6950 5166 5382 5682 5559
123 7565 6375 6242 6636 6677
128 6415 4488 4949 5142 5325
129 7063 5650 5800 6082 5951
130 6409 4090 4404 4594 4542
mean 6626.1 4575.9 4899.4 5159.3 5197.9
SD 612.6 1286.7 998.69 1045.3 963.47
n 7 7 7 7 7





sedentary/MPG (SED/MPG)   
D pre 15 20 25 30
133 6610 3548 3797  4594
134 6413  2105 2323 2505
135 5681 4437 4608 4802 4889
136 5692 3494 3704 3731 3731
137 8075 6182 6549 6560 6860
138 6361 3137 3190 3143 3857
145 7381 1241 1218 1358 1397
147 7074 1170 1197 1251 1426
182 8120 5665 5820 5855 5845
183 7426 3775 4053 4187 4198
194 8418 3648 3861 3940 4050
195 7161  2237 2352 2515
mean 7034.3 3629.7 3528.3 3591.1 3822.3
SD 910.56 1610.9 1668.2 1723.6 1660.3
n 12 10 12 11 12
SE 262.86 509.4 481.57 519.7 479.29
2 days run/MPG (RUN/MPG)   
D pre 15 20 25 30
139 6278 3955 4360 4444 4575
141 5788 3948 4237 4491 4450
142 5130 1611 1818 2268 3234
143 5396 4257 4550 4616 4610
146 6831 1411 2430 2740 2959
151 6474 5765 5883 5724 5523
152 6361 5233 5345 5511 5564
153 5467 4304 4387 4346 4214
197 6555 5950 5858 5860 5917
198 6891 6118 6056 5995 5855
mean 6117.1 4255.2 4492.4 4599.5 4690.1
SD 627.02 1661.5 1432.7 1274.8 1040.3
n 10 10 10 10 10





sedentary, L-NAME perfused (SED/L-N)  
D pre 15 20 25 30
157 6138 3162 3152 3349 3407
158 6324 838 930 1115 1294
159 5800 782 747 792 879
160 7211 5158 5026 4862 3390
171 6167 2151 2260 3195 3231
172 4334 3571 3704 3926 4026
mean 5995.7 2610.3 2636.5 2873.2 2704.5
SD 941.69 1697.8 1657.7 1601 1289.1
n 6 6 6 6 6
SE 384.44 693.13 676.74 653.61 526.27
2 days run, L-NAME perfused (RUN/L-N)     
D pre 15 20 25 30
161 6329 4896 4927 4937 5068
162 7216 5274 5093 3847 5417
163 6272 2914 3722 4058 4181
165 7182 5875 5968 6188 6169
166 7169 5417 5622 5447 5413
168 6538 5065 5158 5166 5215
mean 6784.3 4906.8 5081.7 4940.5 5243.8
SD 452.31 1032.4 768.91 876.15 644.34
n 6 6 6 6 6
SE 184.66 421.46 313.91 357.69 263.05
2 days run/Cold, L-NAME perfused (CRUN/L-N) 
D pre 15 20 25 30
173 7076 5348 5614 5310 5379
175 7500  4674 4968 5172
176 6842 4911 5232 5141 5378
177 7091 5828 6061 6014 6088
178 6479 5332 5342 5566 5467
180 6042 4264 5345 5592 5820
181 6094 5446 5573 5599 5768
mean 6732 5188.2 5405.9 5455.7 5581.7
SD 547.16 539.07 423.1 346.67 319.22
n 7 6 7 7 7
SE 206.81 220.08 159.92 131.03 120.66
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Efficiency (COxSP/O2)    
sedentary (SED)        
D pre 15 20 25 30
119 767.88 183.76 285.97 326.16 427.05
120 707.18 195.07 351.88 431.58 451.87
124 731.29 522.05 588.8 525.68 549.71
125 664.01  261.29 272.04 282.46
126 619.23 192.35 252.21 275.88 343.14
127 634.8 443.81 454.86 445.45 414.41
131 778.68 216.02 228.99 400.02 426.68
mean 700.44 292.18 346.29 382.4 413.61
SD 63.113 150.19 131.72 94.8 84.167
n 7 6 7 7 7
SE 23.854 61.315 49.786 35.831 31.812
2 days run (RUN)    
D pre 15 20 25 30
117 692.9 466.23 482.86 502.12 495.56
118 626.02 322.58 406.06 439.03 473.06
121 789.08 590.92 617.68 636.5 646.6
123 721.99 789.68 793.36  750.35
128 835.29 505.95 579.6 631.63 632.3
129 749.09 580.8 607.58 635.55 625.63
130 720.31 465.74 498.19 527.44 526.94
mean 733.52 531.7 569.33 562.04 592.92
SD 67.33 144.63 124.69 84.51 98.729
n 7 7 7 6 7





sedentary/MPG (SED/MPG)   
D pre 15 20 25 30
133 727.94 549.09 566.89  828.85
134 756.63  299.89 338.69 351.52
135 707.12 560.44 581.42 601.33 603.79
136 596.85 426.49 437.05 440.82 439.65
137 709.48 610.15 622.82 631.06 637.84
138 631.05 377.59 391.8 391.75 464.96
145 748.82 167.98 167.63 173.21 177.03
147 729.08 178.11 176.51 185.19 205.96
182 667.28 525.62 498.08 529.2 516.24
183 724.4 423.68 448.76 474.14 451.33
194 897.92 459.53 480.3 472.6 502.16
195 733.75  316.74 340.2 362.6
mean 719.19 427.87 415.66 416.2 461.83
SD 74.045 152.21 150.23 150.05 180.81
n 12 10 12 11 12
SE 21.375 48.134 43.367 45.241 52.197
2 days run/MPG (RUN/MPG)   
D pre 15 20 25 30
139      
141      
142 715.42 193.05 275.61 338.95 426.93
143 647.84 522.15 548.05 554.59 564.59
146 775.47 199.56 325.68 373.51 388.32
151 713.83 597.17 588.22 577.92 556.89
152 579.14 471.1 466.5 501.38 513.27
153 548.29 437.43 424.21 440.58 418.4
197 807.74 676.87 652.52 683.3 679.8
198 734.76 663.41 661.74 624.22 614.04
mean 690.31 470.09 492.82 511.81 520.28
SD 91.445 188.98 144.77 120.97 102.89
n 8 8 8 8 8





sedentary, L-NAME perfused (SED/L-N)  
D pre 15 20 25 30
157 676.23 410.86 423.76 445.11 461.55
158 657.59 128.04 129.53 164.62 189.95
159 733.47 147.57 135.95 143.69 165.44
160 773.55 606.85 603.61 592.52 499
171 763.38 343.57 361.62 491.62 467.64
172 678.04 524.99 566.11 586.18 593.77
mean 713.71 360.31 370.1 403.96 396.22
SD 49.53 194.91 204.26 201.58 175.93
n 6 6 6 6 6
SE 20.22 79.571 83.387 82.293 71.825
2 days run, L-NAME perfused (RUN/L-N)     
D pre 15 20 25 30
161 755.06 598.91 596.34 605.51 624.98
162 821.24 628.38 586.86 488.55 638.92
163 787.16 406.98 483.1 535.71 527.32
165 764.37 679.74 669.16 684.66 701.46
166 729.27 641.26 670.18 641 669.28
168 782.93 627.32 624.58 652.44 665.74
mean 773.34 597.1 605.04 601.31 637.95
SD 31.414 96.767 69.298 75.065 60.326
n 6 6 6 6 6
SE 12.825 39.505 28.291 30.645 24.628
2 days run/Cold, L-NAME perfused (CRUN/L-N) 
D pre 15 20 25 30
173 765.03 639.77 643.56 650.35 641.58
175 705.21  530.06 577.2 604.49
176 677.36 554.18 577.74 578.16 588.92
177 739.79 643.06 615.79 634.82 646.01
178 709.9 612.54 612.39 636.38 605.29
180 662.06 509.37 645.25 686.3 735.74
181 734.71 667.24 680.46 669.8 698.27
mean 713.44 604.36 615.04 633.29 645.76
SD 36.125 60.522 49.374 42.094 53.92
n 7 6 7 7 7
SE 13.654 24.708 18.662 15.91 20.38
 
129
HSP70 (% of standard)    (SED/L-N) 
(SED)   (SED/MPG)  D  
D   D   157 28 
119 11.3  133 44.4  158 99.3 
120 82.5  134 64  159 77.6 
124 83.4  135 77.1  160 32.7 
125 57.5  136 33  171 30.1 
126 83.7  137 69.5  172 35.4 
127 30.2  138 63.5  mean 50.5167 
131 49.6  182 86.8  SD 30.2758 
mean 56.8857  183 83.2  n 6 
SD 28.6407  mean 65.1875  SE 12.36 
n 7  SD 18.6106  (RUN/L-N) 
SE 10.8252  n 8  D  
(RUN)   SE 6.57982  161 143.2 
D   (RUN/MPG)  162 95.4 
117 105.3  D   163 115.7 
118 116.3  139 172.5  165 165.5 
121 121.8  141 192.4  166 113.1 
123 168.4  142 170.7  168 133.2 
128 166.6  143 185  mean 127.683 
129 159.5  146 47.6  SD 24.8989 
130 165.3  151 126.7  n 6 
mean 143.314  152 138.6  SE 10.165 
SD 27.5517  153 118.1  (CRUN/L-N)     
n 7  mean 143.95  D  
SE 10.4136  SD 47.5708  173 53.7 
   n 8  175 7.5 
   SE 16.8188  176 51.7 
      177 47.8 
      178 47.3 
      180 62.7 
      181 77.9 
      mean 49.8 
      SD 21.5034 
      n 7 





iNOS (% of standard)    (SED/L-N) 
(SED)   (SED/MPG)  D  
D   D   157 391.2 
119 564.9  133 109.2  158 287.6 
120 201.5  134 174.1  159 339.2 
124 165.7  135 303.5  160 279.3 
125 178.8  136 180.5  171 414.8 
126 237.6  137 132.2  172 312.2 
127 260  138 115.3  mean 337.383 
131 236.2  182 801.7  SD 55.4601 
mean 263.529  183 221  n 6 
SD 137.145  mean 254.688  SE 22.6415 
n 7  SD 230.011  (RUN/L-N) 
SE 51.8361  n 8  D  
(RUN)   SE 81.3213  161 105.8 
D   (RUN/MPG)  162 28.3 
117 108.7  D   163 135.4 
118 639  139 271.8  165 360.7 
121 137.3  141 107.6  166 418.8 
123 485.6  142 119.3  168 378.9 
128 349.8  143 725  mean 237.983 
129 259.1  146 166.5  SD 167.077 
130 185.3  151 124.5  n 6 
mean 309.257  152 218.8  SE 68.2091 
SD 195.425  153 149.5  (CRUN/L-N) 
n 7  mean 235.375  D  
SE 73.8635  SD 205.477  173 191.5 
   n 8  175 72.5 
   SE 72.6471  176 191.6 
      177 193.6 
      178 155 
      180 270.5 
      181 589.9 
      mean 237.8 
      SD 166.06 
      n 7 
      SE 62.7648 
 
131
eNOS (% of standard)    (SED/L-N) 
(SED)   (SED/MPG)  D  
D   D   157 52.9 
119 50  133 9.7  158 40.1 
120 48.2  134 10.8  159 47.1 
124 46.8  135 39.4  160 72.3 
125 21.8  136 37.6  171 75.7 
126 22.4  137 40.2  172 94 
127 57.6  138 32.6  mean 63.6833 
131 43.6  182 62.8  SD 20.4216 
mean 41.4857  183 49  n 6 
SD 13.9149  mean 35.2625  SE 8.33708 
n 7  SD 17.9401  (RUN/L-N) 
SE 5.25934  n 8  D  
(RUN)   SE 6.3428  161 31.6 
D   (RUN/MPG)  162 32.9 
117 51  D   163 26.2 
118 75.9  139 50.5  165 19.9 
121 67.7  141 45.8  166 48.8 
123 64.9  142 38.6  168 74.5 
128 37.9  143 75.1  mean 38.9833 
129 50.4  146 73.1  SD 19.8842 
130 20.7  151 81.3  n 6 
mean 52.6429  152 39.2  SE 8.11769 
SD 18.9881  153 13.7  (CRUN/L-N) 
n 7  mean 52.1625  D  
SE 7.17681  SD 22.9536  173 84.5 
   n 8  175 59.1 
   SE 8.11533  176 68 
      177 32.8 
      178 114.3 
      180 112.8 
      181 113.1 
      mean 83.5143 
      SD 31.8601 
      n 7 





CAT (U/mg heart wet weight)       (SED/L-N) 
(SED)   (SED/MPG)  D  
D   D   157 1.6667 
119 1.6133  133 1.8267  158 1.6267 
120 1.3067  134 3.2667  159 1.56 
124 1.96  135 2.9733  160 1.6667 
125 1.42  136 2.52  171 1.84 
126 1.36  137 2.8267  172 1.7333 
127 1.6933  138 3.2133  mean 1.68223 
131 1.3333  182 2.1467  SD 0.09592 
mean 1.52666  183 1.8667  n 6 
SD 0.24083  mean 2.58001  SE 0.03916 
n 7  SD 0.58012  (RUN/L-N) 
SE 0.09102  n 8  D  
(RUN)   SE 0.2051  161 1.72 
D   (RUN/MPG)  162 1.5333 
117 1.7467  D   163 1.6533 
118 1.4933  139 3.4933  165 2.4667 
121 1.1733  141 3.46  166 1.8933 
123 1.6932  142 3.4667  168 1.9467 
128 1.7333  143 3.2267  mean 1.86888 
129 1.5933  146 1.5  SD 0.33024 
130 2.1867  151 2.3467  n 6 
mean 1.65997  152 2.1867  SE 0.13482 
SD 0.30565  153 2.4933  (CRUN/L-N) 
n 7  mean 2.77168  D  
SE 0.11552  SD 0.74662  173 1.8533 
   n 8  175 1.92 
   SE 0.26397  176 2.0533 
      177 1.72 
      178 1.72 
      180 1.6667 
      181 1.8133 
      mean 1.82094 
      SD 0.13483 
      n 7 




MnSOD (U/mg heart wet weight)     
(SED)   (SED/MPG)  (CRUN/L-N) 
D   D   D  
119 1.336  133   173  
120 1.7509  134 1.6067  175  
124 1.9053  135 1.8827  176 0.952 
125 2.0733  136 1.544  177 1.03 
126 2.2293  137 1.8933  178 0.693 
127 1.5547  138 1.852  180 0.982 
131 1.6347  182   181 0.834 
mean 1.78346  183   mean 0.8982 
SD 0.30913  mean 1.75574  SD 0.13557 
n 7  SD 0.16685  n 5 
SE 0.11684  n 5  SE 0.06063 
(RUN)   SE 0.07462    
D   (RUN/MPG)    
117 1.7467  D     
118 1.7786  139 2.052    
121 1.4912  141 2.0427    
123 1.5653  142 1.6213    
128 1.896  143 1.6907    
129 1.4707  146 1.5573    
130 1.7453  151 1.7533    
mean 1.67054  152 1.9693    
SD 0.1618  153 1.9373    
n 7  mean 1.82799    
SE 0.06115  SD 0.19589    
   n 8    




Mass    








119 310 840 0.369
120 330 920 0.3587
124 360 1040 0.3462
125 330 870 0.3793
126 362 960 0.3771
127 304 880 0.3455
131 360 940 0.383
mean 336.57 921.43 0.3655
SD 24.487 66.94 0.0156
n 7 7 7
SE 9.2553 25.301 0.0059









117 290 910 0.3187
118 336 1000 0.336
121 350 940 0.3723
123 306 850 0.36
128 330 1020 0.3235
129 362 1040 0.3481
130 322 940 0.3426
mean 328 957.14 0.343
SD 24.739 67.011 0.0191
n 7 7 7













133 338 960 0.3521
134 336 950 0.3537
135 354 940 0.3766
136 362 930 0.3892
137 372 890 0.418
145 320 860 0.3721
147 336 880 0.3818
138 366 940 0.3894
182 350 950 0.3684
183 344 880 0.3909
194 358 970 0.3691
195 324 860 0.3767
mean 346.67 917.5 0.3782
SD 16.456 40.48 0.0179
n 12 12 12
SE 4.7503 11.686 0.0052








139 366 1050 0.3486
141 330 930 0.3548
142 326 930 0.3505
143 336 1040 0.3231
146 352 920 0.3826
151 342 1010 0.3386
152 352 960 0.3667
153 340 940 0.3617
197 350 1010 0.3465
198 318 930 0.3419
mean 341.2 972 0.3515
SD 14.336 50.288 0.0164
n 10 10 10





D body (g) heart (mg) ratio (g/mg) 
157 350 910 0.3846
158 354 910 0.389
159 358 940 0.3809
160 368 1000 0.368
171 324 920 0.3522
172 316 920 0.3435
mean 345 933.33 0.3697
SD 20.425 34.448 0.0185
n 6 6 6
SE 8.3387 14.063 0.0076
(RUN/L-N) 
D body (g) heart (mg) ratio (g/mg) 
161 312 920 0.3391
162 300 870 0.3448
163 312 920 0.3391
165 312 940 0.3319
166 312 900 0.3467
168 292 880 0.3318
mean 306.67 905 0.3389
SD 8.641 26.646 0.0062
n 6 6 6
SE 3.5277 10.878 0.0025
(CRUN/L-N) 
D body (g) heart (mg) ratio (g/mg) 
173 336 1080 0.3111
175 294 920 0.3196
176 292 880 0.3318
177 312 950 0.3284
178 350 1100 0.3182
180 362 1070 0.3383
181 316 930 0.3398
mean 323.14 990 0.3267
SD 27.052 90.185 0.0108
n 7 7 7




Body Temperature (°C)      
Sedentary  Run   Cold Run 









173 37.6 107 40.8 41.7 173 37.3 34.1 
174 37.2 108 40.7 41 174 35.4 32.3 
175 37.8 109 40.8 41.7 175 37.3 35.9 
176 37.7 110 40.4 40.4 176 36.8 36 
177 38 111 40.4 41.3 177 35.3 33.7 
178 38    178 35.2 33.8 
mean 37.717  40.62 41.22  36.217 34.3 
SD 0.2994  0.2049 0.545  1.0226 1.4213 
n 6  5 5  6 6 





Anti-Oxidant - A substance that can reduce or destroy oxidants. 
Aortic Flow (AF) - The volume of blood flowing through the aorta per minute, 
normalized for the size of the heart in milliliters per minute per gram of heart 
wet weight. 
Cardiac Function (COxSP) - An index of external work that an isolated working heart is 
performing during perfusion. Calculated as the product of the cardiac output and 
peak systolic pressure. 
Cardiac Output (CO) - The volume of blood the left ventricle of the heart ejects per 
minute, normalized for the size of the heart. Calculated as the sum of the 
coronary flow and the aortic flow in milliliters per minute per gram of heart wet 
weight. 
Cardioprotection - Improved intrinsic tolerance of the myocardium to an imposed stress. 
Catalase (CAT) - The antioxidant enzyme that catalyzes the conversion of hydrogen 
peroxide to H2O and O2. 
Coronary Flow (CF) - The volume of blood flowing through the coronary vasculature 
per minute, normalized for the size of the heart in milliliters per minute per gram 
of heart wet weight. 
Efficiency - The quotient of cardiac function (COxSP) and oxygen consumption. 
Free Radicals - A highly reactive class of molecules, categorized by the presence of an 
unpaired electron in the outer orbital. 
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Glutathione (GSH) - A tri-peptide with a reduced sulfhydryl group, which is capable of 
being oxidized by glutathione peroxidase during the conversion of hydrogen 
peroxide to water. 
Glutathione Peroxidase (GPX) - The anti oxidant enzyme that catalyzes the conversion 
of hydrogen peroxide to H2O. 
Heart Rate (HR) - The rate at which the heart contracts, in beats per minute. 
Heat Shock Protein 72 (HSP72) - The 72 kilo Dalton inducible form of a protein in a 
class of proteins called stress proteins. Implicated in the facilitation of 
cardioprotective mechanisms. The abbreviation HSP70 represents both the 
constituiative and inducible form of the protein. 
Ischemia- Period of no-flow in the myocardium during which the delivery of substrates 
and the removal of metabolic byproducts is prevented. 
Isolated Heart Perfusion - Procedure for measuring the function of the heart in vitro by 
providing artificial blood flow to the heart and allowing the heart to pump 
independently from the organism. 
Krebs-Henseleit Buffer - Solution used to perfuse the hearts containing essential ions 
and substrates at an osmolarity and pH similar to that observed in vivo. 
Lactate Dehydrogenase (LDH) - The enzyme which catalyzes the reversible reaction 
from Lactate to Pyruvate. It is normally located in the cytosol of all cells and its 
presence in the coronary effluent indicates sarcolemma damage, which may lead 
to cellular necrosis. 
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Langendorff Perfusion - Isolated heart perfusion in which the heart does not perform 
any external work, as the heart only contracts against a retrograde perfusion 
pressure. 
Lω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) - Competitive inhibitor of 
all three isoforms of nitric oxide synthase. 
N-(2-Mercaptopropionyl)glycine (MPG) - Pharmacological, Potent free radical 
scavenger. 
Myocardium - The heart muscle. 
Nitric Oxide (NO) - A reactive nitrogen species produced by the action of nitric oxide 
synthase, which is responsible for signaling vasodilatation and initiating other 
cell-signaling events. 
Nitric Oxide Synthase (NOS) - The enzyme that produces nitric oxide during the 
enzymatic conversion of L-arginine to L-citrulline. The three predominant 
isoforms include: eNOS, the endothelial isoform; iNOS, the inducible isoform; 
and nNOS the neuronal isoform. 
Oxidative Stress - A stress in an organism caused by increased production of free 
radicals or reactive oxygen species. 
Preconditioning - Any treatment capable of triggering a cardioprotective response in the 
myocardium that can protect against subsequent stresses. Preconditioning falls 
into two general categories, the early and late phase. The early phase appears 
minutes following a treatment, and is generally characterized by post-
translational modification of existing proteins. The late phase occurs anywhere 
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from hours to days following treatment, and is generally characterized by de-
novo synthesis of proteins. 
Reactive Oxygen Species (ROS) - A class of highly reactive molecules, including free 
radicals, which can cause oxidative stress. 
Superoxide Dismutase (SOD) - The anti oxidant enzyme that catalyzes the conversion 
of superoxide to hydrogen peroxide. The predominant isoforms include: 
MnSOD, located in the mitochondria; and CuZnSOD, located in the cytosol of 
the cell. 
Systolic Pressure (SP) - The maximum pressure in the aorta during the contraction of 
the left ventricle, measured via the placement of a pressure transducer at the 
level of the aortic valve. 
Uncoupling Protein 2 (UCP2) - The isoform of a protein, predominantly expressed in 
cardiac tissue, responsible for the uncoupling of mitochondrial respiration. 
Working Heart Perfusion - Isolated heart perfusion in which the heart functions in a 
physiological, recirculating manner while producing measurable external work. 
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